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ABSTRACT 
Multidrug resistance (MDR) is one of the major obstacles in cancer chemotherapy, 
accounting up to 50% in cancer-related deaths. A known mechanism of MDR is the 
overexpression of adenosine triphosphate-binding cassette (ABC) transporters, 
including P-glycoprotein (P-gp/ABCBl), multidrug resistance-associated protein 1 
(MRPl/ABCCl) and breast cancer resistant protein (BCRP/ABCG2), which actively 
transport drugs out of the cancer cells. Currently, numerous ABC transporter 
inhibitors have been identified, but none of them was successfully used in clinic due 
to unwanted adverse effects and inadequate efficacy. On the other hand, the idea to 
use natural products including traditional Chinese medicine (TCM) as alternative 
sources for the identification and development of new generation of ABC inhibitors 
attracts more attentions recently.. 
In this study, polyoxypregnane compounds (POPs) isolated from a TCM herb 
M—nia tenacissima (Caulis Marsdeniae Tenacissimae,通關藤），which was 
found to be effective in enhancing the cytotoxicity of chemotherapy, were screened 
for active component(s) in circumventing MDR. The underlying mechanism of the 
selected POPs, which effectively modulated P-gp-mediated MDR was further 
delineated. Interestingly, the most abundant POPs from M. tenacissima were found to 
be ineffective in circumventing P-gp mediated MDR in vitro. However, their 
metabolites produced after incubating in human intestinal microbiota solution were 
found to be effective, thus representing an example of the “prodrug” strategy. These 
metabolites of selected POPs after oral administration of M. tenacissima in mice 
were investigated and the in vivo toxicity o f M tenacissima was studied as well. 
i 
Among the POPs isolated from M tenacissima, 11, 6 and 3 of them were found to be 
effective in circumventing P-gp-, MRPl- and ABCG2-mediated MDR, respectively. 
Importantly, three of them, namely POP65, POP86 and POP87, circumvented MDR 
by modulating all three transporters. An acetyl group at the R] position of POPs was 
found to be important in circumventing MDR. Six effective POPs (POP53, POP55, 
POP56, POP62, POP63 and POP66) inhibited P-gp-mediated efflux, increased the 
intracellular concentration of P-gp substrate anti-cancer drug and stimulated P-gp 
ATPase activity to circumvent P-gp-mediated MDR, but without down-regulation of 
P-gp protein expression. M. tenacissima extract also showed in vitro P-gp mediated 
MDR reversal effect. Three most abundant POPs (POP68, POP69 and POP70) were 
found inactive in vitro, but were metabolically converted to three corresponding 
effective POPs (POP62, POP63 and POP66) by intestinal microbiota, and thus 
produce their activity after oral administration. Moreover, these three most abundant 
POPs did not induce any in vivo toxicity towards various organs in mice after oral 
administration of them in a herbal fraction. 
In conclusion, M tenacissima circumvented MDR, mainly due to the effective POPs, 
which either occur naturally and/or metabolized from the ineffective ones by 
intestinal enzymes in the body. M. tenacissima may serve as an example for 
identifying ABC transporter inhibitor from TCM. Furthermore, POPs have a 
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Chapter I. Iiilrodiiclioti 
CHAPTER 1. INTRODUCTION 
1.1 Multidrug resistance (MDR) 
Multidrug resistance (MDR) is the ability of cancer cells to develop simultaneous 
resistance to anti-cancer drugs which structures and mechanisms of action may be 
completely different.' 
1.1.1 Cancer 
Cancer is a group of diseases caused by the spread of abnormal cells displaying 
uncontrolled growth. Cancer is one of the leading causes of death worldwide. It 
accounted for 7.9 million deaths in 2007, with an estimated 12 million deaths in 
2030.2 It is the second most common cause of death in the US and it accounts for 
nearly 1 of every 4 deaths.' In Hong Kong, cancer is the first leading cause of death 
over the last decade.' Cancer can be caused by both external factors and internal 
factors. Cancerous cells acquire ability to evade apoptosis, sustain angiogenesis and 
develop mechanisms for replication, invasion and metastasis.' The treatment options 
for cancer are surgery, radiation, chemotherapy, hormone therapy, biological therapy 
and targeted therapy. 
1.1.2 Mechanisms of MDR in cancer 
Resistance preexisting at the time of diagnosis or acquired during treatment are 
termed intrinsic drug resistance and acquired drug resistance respectively.^ 
Intrinsic drug resistance is the phenomenon of cells resistant to chemotherapy 
I 
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regardless of their cancerous nature. This may due to the cancer type, e.g. brain 
tumor is intrinsically resistant to chemotherapy due to inadequate drug delivery, or 
gene mutation before initial treatment of chemotherapy and thereby enabling evasion 
from effective chemotherapy. 
Acquired drug resistance may develop via prolonged treatment of chemotherapy and 
it accounts for the decreased sensitivity of effective chemotherapy after prolonged 
treatment and the resistance in recurrent cancer cells/ Multiple drug resistance 
(MDR) is a condition enabling a disease-causing organism to resist distinct drugs or 
chemicals of a wide variety of structure and function targeted at eradicating the 
organism. 
As early as 1950, research had already been done to demonstrate the ability of a 
sensitive leukemic strain to develop drug resistance.^ MDR was originally described 
as the active outward transport of anthracyclines and vinca alkaloids from murine 
Ehrlich ascites tumor cells.^ 
In addition to the drug exposed to the cancer cells before, the cancer cells might 
subsequently develop cross-resistance to several unexposed and structurally 
unrelated chemotherapeutic agents that do not necessarily have a common 
mechanism of action, resulting in MDRJO 
The observation of cells mutated to survive from chemotherapy before they turn into 
malignant tumor,^ the reappearance of tumor after successful treatment and the 
observation of stem-like cancer cells raise the cancer stem cells (CSCs) theory. 
2 
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Moreover, CSCs acquire most of the MDR mechanism discussed below. 
N画erous molecular mechanisms have been generalized to explain how cancer cells 
acquired the MDR phenotype,丨⑷ which are summarized as follows: 
1.1.2.1 Drug entry 
The first obstacle for a drug to access the intracellular compartment is the interaction 
with plasma membrane. This is determined by uptake transport, efflux transport and 
metabolism in the lipid bilayer. The solute carrier (SLC) superfamily contributes to 
the decreased uptake of drug into the cells, an example of which was caused by a 
decrease or loss of SLC19A1 expression and genetic polymorphisms in 
methotrexate-resistant tumors.^'"^^ On the other hand, ATP-dependent drug efflux 
pumps such as ATP-binding cassette (ABC) transporters, RLIP76/RALBP1 丨？ and 
18 
copper transporters are involved in drug efflux. Their overexpression was known to 
mediate drug resistance. The role of ABC transporters in MDR wil l be discussed in 
more detail under subheading 1.1.4. 
1.1.2.2 Drug metabolism 
Active drugs are converted into inactive metabolites in the intracellular compartment, 
mainly by phase I and phase I I metabolic enzymes. Cytochrome P450 enzymes 
(CYPs) and epoxide hydrolases play a vital role in phase I or oxidative metabolism. 
The metabolites converted by microsomal CYP and epoxide hydrolases can then be 
conjugated by phase I I metabolic enzymes and efflux by transporters such as the 
members of the ABCC transporter family.'^ Increased metabolism of anti-cancer 
Chapter I. Introdiiclioi) 
drug by overexpressing lipid messenger like ceramide has also been reported to take 
part in drug resistance.^^ 
CYP also plays a role in MDR and induction of CYP by anticancer drug has been 
reported to contribute to MDR.^''^^ ^^^ coordinate regulation of CYP enzymes and 
ABC transporters has been shown to generate better substrates of ABC transporters 
for efflux (by CYP) and to prevent saturation of CYP (by ABC transporters via 
subsequent entry of drug into the cell).^^ In chemotherapy, this synergism played by 
CYP and ABC transporters can remarkably decrease the efficacy of 
chemotherapeutic drugs. 
A number of phase I I metabolic enzymes, including glutathione-S-transferases, 
UDP-glucuronosyltransferases, sulfotransferases and arylamine N-acetyltransferases, 
are known to be responsible for the metabolism of anticancer drugs. These enzymes 
help converting xenobiotics into metabolites which are then effluxed by ABC 
transporters.'^ Genetic polymorphisms in phase I and phase I I metabolic enzymes 
were found to be associated with overall survival in cancer patients.24 
1.1.2.3 Drug sequestration 
Besides intracellular metabolism, drug sequestration also plays a pivotal role in 
hindering the drug reaching the target site. Chemotherapeutic drugs that are weak 
bases such as the anthracyclines and vinca alkaloids are permeable in their neutral 
form but become relatively impermeable in their protonated form. Acidic organelles 
help protonate chemotherapeutic drugs and aid in sequestration of them from the 
4 
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nucleoplasm and cytosol. Resistant cancer cells have been found to have highly 
acidic organelles, thereby enhancing the drug sequestration in the organelles, 
decreasing accumulation of chemotherapeutic drugs in the cytosol and facilitating 
further secretion of chemotherapeutic drugs.'^'^^ Besides, the ABC drug transporter 
ABCA3 was discovered to be overexpressed in membranes of lysosomes and 
mediate drug sequestration to lysosomes in resistant cancer cells.]? 
1.1.2.4 Mechanisms activated after nuclear entry 
Chemotherapeutic drugs which are able to evade the above mechanisms will 
eventually reach the nucleus of the cell. Most chemotherapeutic drugs work 
preferentially on proliferating cells by causing extensive DNA damage, which 
subsequently leading to cell cycle arrest and cell death. Complex DNA repair 
pathways, on the other hand, reduce the efficacy of chemotherapeutic drugs by 
repairing DNA damages. Modification of signaling pathways, which monitors the 
DNA and genetic damage of a cell, contributes to MDR. 28,29 
1.1.2.5 Evasion of drug-induced apoptosis 
Apoptotic pathways, initiated by chemotherapeutic drugs, can also be evaded by 
alteration in regulatory proteins like overexpression of FLIP and deregulation of the 
Bcl-2 family proteins and ultimately results in drug resistance.]。，）！ 
1-1.3 Approaches in treating MDR 
MDR is well-known to be multifactorial, apparently not limited to the mechanisms 
5 
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mentioned above. With the advances in understanding about the various regulatory 
and signaling pathways, more novel drug targets are revealed for the circumvention 
of drug resistance. Our study is focusing on those related to drug transporters. 
1.1.3.1 Overcoming MDR by inhibiting transporters 
There are two general approaches to overcome resistance involving transporters. 
One is to co-administer a drug that inhibits the activity of efflux transporters, such as 
the combinational use of valspodar (PSC833, a specific P-gp inhibitor) with 
chemotherapeutic drugs in P-gp-overexpressing cancer cells.33,34 Another one is to 
design chemotherapeutic drugs which are not affected by the presence of 
transporters. 13 Undoubtedly, drugs such as curcumin having the ability to evade the 
efflux at the same time cytotoxic to cancer cells are also highly considered to be used 
in co-administration with other chemotherapeutics.^^'^^ 
1.1.3.2 Overcoming MDR by altering signaling pathway 
DNA repair pathway contributes to MDR. It follows that regulating DNA repair 
pathway by tumor suppressor genes such as NPRL2 represents a novel strategy to 
circumvent drug resistance in cancer.^ ^ Designing drugs to inhibit the overexpression 
of regulatory proteins in apoptotic pathway has also been investigated for the 
reversal of MDR. Recently, obatoclax, a small molecule targeting the pro-survival 
factors in the Bcl-2 family protein, was found to sensitize resistance cancer cells.^^ 
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1 • 1.4 ATP Binding Cassette (ABC) Transporters 
Among the mechanisms mentioned above, adenosine triphosphate-binding cassette 
(ABC) superfamily is the most extensively studied efflux transporters mediating the 
resistance to chemotherapeutic drugs. The name "ABC transporters" was introduced 
in 1992 by Chris Higgins.'^ In humans, 48 ABC transporter genes are known and are 
grouped into ABCA to ABCG, a total of seven, subfamilies.^ 
ABC transporters are integral membrane proteins that typically utilize cellular energy 
to translocate solutes across cellular membranes. ABC transporters are large 
membrane-bound proteins consisting of two nucleotide-binding domains (NBDs) and 
two transmembrane domains (TMDs).39，4⑷ These transporters have to recognize the 
substrates and then sequester them from the membrane before they can do any 
transportation."^^ 
1.1.4.1 P-glycoprotein (P-gp) 
P-glycoprotein (P-gp) was first named by RL Juliano and V Ling in 19708.^ ^ It 
belongs to the ABCB subfamily. The ABCB, also called multidrug resistance 
(MDR)/(TAP), subfamily is composed of four full transporters and seven half 
transporters. ABCB subfamily is the only human subfamily to have both types of 
transporters."^^ 
P-gp is widely distributed in many parts of our bodies. However, it was found to be 
concentrated in a small number of specific sites. Strong expression of P-gp can be 
found in endothelial cells of capillary blood vessels in the brain and several other 
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organs including intestine, testes and skin.^ ^ '^^ ^P-gp is expressed primarily in the liver 
and blood brain barrier, and is thought to be involved in protecting cells from toxic 
agents. In human tumors, the frequency of P-gp expression was studied and is more 
remarkably expressed in renal carcinoma, colon carcinoma, adrenal carcinoma and 
teratocarcinoma.45 
P-gp is encoded by the ABCBl (MDRl) gene. The structure of human P-gp was 
hypothesized to show a high degree of flexibility to facilitate transport of its 
substrates. This may be due to more than one substrate binding sites in P-gp and the 
flexibility in the mechanism of t r a n s p o r t . T h e ABCBl gene is subject to control 
by a variety of internal and external stimuli, including differentiation signals, heat 
shock, cytokines, hormones, and a variety of toxic insults.49 
Early investigations in MDR cell lines found that there was an up-regulation of P-gp 
protein expression.^^ It was later confirmed that P-gp is a MDR transporter and 
account for the MDR phenomenon. 
Tackling the MDR problem in chemotherapy is a pressing need in cancer treatments. 
In the 1980s, the first known P-gp inhibitor, verapamil, was reported to increase the 
intracellular concentration of anticancer agents in multidrug resistant cells by binding 
to P-gp and inhibiting the P-gp-mediated efflux.^^ It fueled hopes that anticancer 
drug resistance could be reversed by inhibiting drug efflux. To improve the 
chemotherapy of multidrug-resistant tumors, a range of P-gp inhibitors has been 
developed^' and numerous clinical trials have been carried out to test this MDR 
reversal hypothesis. These trials used drugs that were readily available for use in the 
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clinic based on approved medical indications and were determined to be P-gp 
inhibitors in the laboratory. However, these drugs were only weak P-gp inhibitors in 
v/vo and the non-randomized nature of the trial design made it difficult to draw 
definitive correlation between the enhancements of therapeutic response to the 
inhibition of P-gp mediated resistance. As second and third generation P-gp 
inhibitors were developed, many of them were found to inhibit cytochrome P450 and 
impair drug clearance.'' Table 1.1 summarized the first three generations of P-gp 
inhibitors.53 This prompted decreases in drug dosing to prevent excessive toxicity, 
thus undermining any benefit that could be obtained from having a drug efflux 
inhibitor. The design of potent MDR inhibitors devoid of other pharmacological 
activities has thus become a desirable goal to test the MDR reversal hypothesis in the 
clinics. Nevertheless, attempts to translate the MDR transporter into clinical targets 
have been unsuccessful and no significant survival benefit of P-gp inhibition can be 
achieved. 54 
Table 1.1 The first three generations of P-gp inhibitors 
Generation P-gp inhibitors 
First generation verapamil, cyclosporine A, tamoxifen 
Second generation PSC833 (valspodar), VX-710 (biricodar) 
Third generation LY335979 (zosuquidar), XR9576 (tariquidar), GF120918 
(elacridar), OC144-093 (ontogen) 
1.1.4.2 Multidrug resistance-associated protein 1 (MRPl) 
Occurrence of drug resistance in human lung tumors without overexpression of P-gp 
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suggested that other alternative resistance mechanisms exist.'' A second type of drug 
efflux pump was subsequently discovered in doxorubicin-selected lung cancer cell 
line H69AR and was identified as the multidrug resistance-associated protein 
(MRP1).56 
The MRP, also called cystic fibrosis transmembrane conductance regulator (CFTR), 
is now categorized officially under the ABCC transporter subfamily. It contains 12 
full transporters. Among them, the ABCCl (MRPl) gene is known to mediate 
multidrug resistance.40 Unlike P-gp, which is located in the apical membranes of 
epithelial cells, MRPl is located basolaterally or laterally and tends to pump drugs 
into the body, rather than excrete them into the bile, urine or gut.^^ MRPl was also 
suggested to be particularly well expressed in skeletal muscle.'^ Overexpression of 
MRPl can be found in many multidmg-resistant cell lines derived from various 
tumor types such as lung cancers, colon carcinoma and different forms of leukemia.^^ 
The preferred substrates for MRPl are organic anions and MRPl is one of the 
elusive glutathione-S-conjugate (GSX) pumps which are able to transport drugs 
conjugated to GSH out of the cell.^^ 
1.1.4.3 Breast cancer resistant protein (BCRP) 
Breast cancer resistance protein (ABCG2/BCRP) was first cloned from a heavily 
drug-selected breast cancer cell line MCF-7/AdrVp.^^ Since P-gp or MRPl are not 
expressed in the MCF-7/AdrVp cell line, ABCG2/BCRP is presumably responsible 
for the drug resistance phenotype. Interestingly, the same gene was discovered 
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almost simultaneously by three research groups, thus giving it three names (BCRP, 
ABCP and MXR) in the 1990,s, 6丨,62 This BCRP/ABCP/MXR gene was later assigned 
the name “ABCG2” by the Human Gene Nomenclature Committee, which falls into 
the ‘‘G’’ subfamily of ABC transporters. 
The human ABCG subfamily contains six half transporters and there are only 5 
ABCG genes found in human genome.'^^In contrast to P-gp and MRPl, ABCG2 is 
considered as half transporter, which needs to form a homodimer by a disulfide (S-S) 
bridge for drug transportation.^^ ABCG2 is physiologically expressed in a variety of 
tissues, most abundantly in the liver and intestinal epithelia.^ " '^^ ^ ABCG2 is localized 
in the apical region in cells.^^ It is believed that ABCG2 plays a role in pumping out 
toxic metabolites to the maternal blood supply in order to protect fetus.^ o 
The substrates of ABCG2 can be both positively and negatively charged.^ ^ Numerous 
substrates have been identified for ABCG2 including many cytotoxic drugs, 
detoxified metabolites, toxins and carcinogens.^ 
1.1.4.4 ABC drug transporters and drug absorption 
Being a major superfamily in membrane transporters, ABC drug transporters have 
been suggested to take part in drug disposition, therapeutic efficacy and adverse drug 
reactions in vivo. The in vivo role of ABC drug transporters is demonstrated by gene 
knockout in animal species and by loss-of-function genetic variants in humans.^ ^ 
Clinical pharmacokinetic drug-drug interaction studies investigated the interaction 
between ABC drug transporters, particularly P-gp and ABCG2, and metabolic 
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enzymes in drug absorption and elimination. P-gp and ABCG2 play a role in 
intestinal drug absorption and biliary and urinary drug excretion. They limit the oral 
bioavailability and transportation across the blood-brain barrier and intestinal 
epithelia.67’68 ABCG2 also helps inhibiting the drug entry via blood-testis barrier and 
the maternal-fetal barrier of some selected substrates.^^ As mentioned above, P-gp 
and ABCG2 are localized on the apical membranes of epithelial cells for drug 
excretion whereas MRPl is located basolaterally and tends to transport drugs into the 
body. Nevertheless, MRPl plays a vital role in preventing the entry of drugs into the 
cerebrospinal fluid/^ 
1.2 The Use of Traditional Chinese Medicine (TCM) in circumventing 
P-gp-mediated MDR 
Natural products and derivatives are rich sources of novel therapeutics/^ The fourth 
generation of P-gp inhibitor has been highly focusing on the use of natural products 
to uncover novel lead compounds.^^ TCM, involving various kinds of natural 
products in treating diverse diseases, gives us hints to trace for effective compounds 
in treating MDR cancer. 
1.2.1 Active ingredients in TCM - Alkaloid 
Tetrandrine, a calcium channel blocker, is a bisbenzylisoquinoline alkaloid isolated 
from the root of Stephania tetrandra. Tetrandrine was reported to reverse MDR in 
俞o and modulate P-gp-mediated drug efflux/^"^^ Synergistic anticancer effect from 
a combination of tetrandrine with doxorubicin or vincristine in vitro has also been 
reported.77 It was effective in reducing the P-gp expression/^ In mice bearing 
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resistant MCF-l/DOX cells, tetrandrine potentiated the antitumor activity of 
doxorubicin without causing significant increase in toxicity/^ A synthetic 
halogenated form of tetrandrine was found to increase vinblastine accumulation in a 
dose-dependent manner in a resistant P388/DOX cell line and prolong the life-span 
of tumor-bearing mice up to 25% without any side effects.^^ In a recent clinical trial, 
38 patients with acute myeloid leukemia were treated with a combination of 
tetrandrine with daunorubicin, etoposide and cytarabine, the drugs were well 
tolerated and found to demonstrate encouraging antileukemic effects.^' 
Matrine is a quinolizidine alkaloid found in Sophora alopecuroides. In a resistant 
K562/DOX cell line, matrine at a non-toxic dose of up to 50 .ug/mL increased the 
intracellular accumulation of doxorubicin and induced its apoptotic effect. ^ ^ Matrine 
was also showed to enhance the cytotoxicity of vincristine in a resistant K562/VCR 
cell line.83 Matrine was proposed to work by reducing P-gp expressions^ 
Tetramethylpyrazine, an active alkaloid found in Ligusticum waUichii, is a calcium 
channel blocker. In a P-gp-overexpressing resistant HL-60/VCR cell line, 
tetramethylpyrazine significantly reversed MDR towards various drugs including 
vincristine, duanorubicin and doxorubicin.^'^ Tetramethylpyrazine was shown to 
remarkably reduce drug efflux (by as much as 50%) in a P-gp-overexpressing 
resistant MCF-7/D0X cell line using a hypothesized material transport model.^^ 
When used together with p-elemene, tetramethylpyrazine exhibited even stronger 
MDR reversal effect in a resistant K562/DOX cell line.^^ Tetramethylpyrazine was 
found to decrease P-gp expression in a resistant HepG2/D0X cell line.^^ However, 
the reduction in P-gp expression was not universally observed. For instance, P-gp 
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level was not altered despite MDR reversal in tetramethylpyrazine-trcaled 
K562/DOX cells.88 
Peimine, also named verticine, is a cevanine type isosteroidal alkaloid found in bulbs 
of Fritillaria thunbergii and other Fritillaria species.^ '^^ ^ In resistant K562/DOX and 
HL-60/DOX cell lines, peimine was able to increase intracellular concentration of 
daunorubicin and reverse MDR probably through inhibiting P-gp expression.^' 
Berbamine is a calcium channel blocker and present in Mahonia fortunei. In 
K562/DOX cell line, berbamine inhibited cell growth by inducing apoptosis in a 
dose-dependent manner. Interestingly, it also reduced P-gp expression and therefore 
increased the intracellular concentration of rhodamine-123 and d o x o r u b i c i n . I n 
MCF-7/D0X cell line, its derivative 6>-(4-ethoxyl-butyl)-berbamine showed strong 
MDR reversal effect by enhancing G2/M arrest and increasing the intracellular 
accumulation of doxorubicin.^^ 
1.2.2 Active ingredients in TCM - Saponin 
Ginsenosides are the major active components found in Panax ginseng. 
Ginsenosides are mainly triterpenoid dammarane derivatives. Several ginsenodies 
including Rgl, Rg3, Re, Rc and Rd were found to inhibit drug efflux.^^ Interestingly, 
using a combination of purified saponins containing Rbl, Rb2, Rc, Rd, Re and Rgl, 
MDR reversal effect was observed whereas individual component of the 
ginsenosides alone did not have any effect.^^ Ginsenosides were also found to be 
effective in reversing MDR in K562/VCR and K562/DOX cell lines,^^ and the effect 
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was dose-dependent in K562/DOX. P-gp expression was found to be decreased but 
bcl-2 expression was not.^ In another study, Rbl was found to reverse MDR in 
K562/HHT and HL60/VCR cell lines.99,湖 
P(inax notoginseng total saponins was able to reverse MDR in MCF-7/D0X and 
K562/VCR cell lines by decreasing P-gp expression. 
1.2.3 Active ingredients in TCM - Flavonoid 
Quercetin is one of the most widely distributed flavonoids in natural products 
including TCM herbs like Sophora japonica. Quercetin inhibited the binding of heat 
shock factor at the MDRl promoter, thereby decreasing MDRl transcription and 
reducing P-gp expression」。3 Quercetin was also found to inhibit the overexpression 
of P-gp mediated by arsenite.^ in HL-60/DOX and K562/DOX cell lines, quercetin 
was reported to decrease P-gp expression. It was suggested that the MDR 
reversal effect of quercetin was mediated by its action on mitochondrial membrane 
potential and the induction of apoptosis rather than the inhibition of P-gp-mediated 
drug efflux. Furthermore, the actual species that lead to MDR reversal might be 
quercetin derivatives rather than quercetin itself.浙 Among many active flavonoids, 
quercetin was less potent than kaempferol but more active than genistein and 
daidzein in reversing MDR. In fact, genistein and daidzein had no effect on P-gp 
expression.刚 Although quercetin may be a potential MDR reversing agent, lethal 
drug-drug interaction between quercetin and digoxin has been reported. Quercetin 
(40 mg/kg) was found to elevate the peak blood concentration of digoxin, which is a 
P-gp substrate, by 413% and lead to sudden death of two over three pigs t e s t e d . ^ 
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Curcumin, the major component in Curcuma longa, has been studied for a variety of 
biological activities. Curcumin was found to inhibit the transport activity of all three 
major ABC transporters, P-gp, MRPl and ABCG2."^ It was found to reverse MDR 
m K562/DOX cell line by decreasing P-gp expression in a time-dependent manner」丨‘ 
Curcumin was also effective in inhibiting P-gp in SGC7901/VCR cell line.^'^ 
Moreover, it was found to be useful in reversing MDR associated with a decrease in 
bd-2 and survivin expression but an increase in caspase-3 expression in a 
COCl/DDP cell line. 113 Curcumin derivatives were found to reverse MDR by 
inhibiting P-gp efflux. A structure-activity relationship study of the curcumin 
derivatives revealed that a chlorine substituent at the meta- or para- position on 
benzamide is associated with a better MDR reversal a c t i v i t y . O n the other hand, 
modifying curcumin into bisdemethoxycurcumin could lead to a greater inhibition of 
P-gp express ion. 115 Tetrahydrocurcumin, the major metabolite of curcumin, was also 
able to inhibit all three major ABC transporters."6 It was suggested that curcumin 
could induce atypical and caspase-independent cell death in MDR cells to overcome 
the MDR phenomenon . 117 In leukemic cells collected from 78 childhood leukemia 
patients, curcumin was found to reduce P-gp expression. a specialized 
nanoemulsion formulation of curcumin has been developed to enhance the drug 
delivery efficiency into the cells. It was found that this nanoemulsion formulation of 
curcumin was able to down-regulate P-gp expression, inhibit the NFKB pathway and 
promote apoptotic response more efficiently when compared with the conventional 
solution dosage form."o，ii9 
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1.2.4 Active ingredients in TCM - Others 
Schizandrins, the active constituents of Fructus Schizandrae and the crude herbal 
extract were investigated for their MDR reversal effect. Schizandrin A was found to 
be the most potent in reversing MDR by enhancing apoptosis, and down-regulating 
P-gp and total protein kinase C expression. The crude extract of Fructus Schizandrae 
also showed positive reversal effect in vivo}^^ Deoxyschizandrin and 丫-schizandrin, 
among the nine dibenzo[a,c]cyclooctadiene lignans examined, were demonstrated to 
enhance intracellular drug concentration and induce cell cycle arrest at the G2/M 
phase when combined with sub-toxic dosages of doxorubicin.⑵ Gomisin A, on the 
other hand, altered P-gp-substrate interaction by binding to P-gp simultaneously with 
substrates, m 
1.3 Polyoxypregnane compounds (POPs) 
1.3.1 Characterization 
Marsdenia tenacissima (Roxb.) Moon. ( M tenacissima) is a plant of the 
Asclepiadaceae family distributed mainly in the southwest of mainland China, 
mainly Yunnan province, and its dried rhizomes and roots have been used for the 
treatment of cancer.⑵ The dried stem of M. tenacissima, known as 
'Tong-guang-teng', is mainly used in the Yunnan province by nationality tribes， 
especially the Wa nationality tribe, in Chinese folk medicine. In the 1977 edition of 
Chinese Pharmacopoeia, M. tenacissima has been recorded as Caulis Marsdeniae 
Tenacissimae and the dried stem has cough-relieving, phlegm-expelling and 
antiasthmatic effect. It is used in chronic bronchitis and bronchial asthma.' 24 The 
entire plant and the stem part of M. tenacissima have been reported to be used for the 
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treatment of cancer」25 Different formulations of M tenacissima have been used for 
the treatment of chronic bronchitis, tracheitis, gastric carcinoma, liver cancer, 
esophageal cancer and hepatocellular carcinoma 
mm 
Figure 1.1 Photos of A) M. tenacissima adopted from www.zgyaocai.com and B) 
Caulis Marsdeniae Tenacissimae adopted from www.plantphoto.cn. 
1.3.2 POPs isolated from M. tenacissima 
Polyoxypregnane compounds (POPs) have been isolated from M. tenacissima. Since 
1980, more than forty POP derivatives have been characterized. ^ ^^  POPs in the 
ethanol extraction of the stem of M. tenacissima showed cytotoxic activity against 
human epidermoid carcinoma cells in mouth (KB ce l ls ) .However , the active 
component(s) for the anticancer activities of M. tenacissima remains unclear. 
Recently, two derivatives of POPs isolated from M. tenacissima have been reported 
to increase drug sensitivity in P-gp-overexpressing human hepatoma cells.^^^ 
In the search for further anticancer constituents or MDR-reversal agents, a series of 
30 POPs has been isolated from M. tenacissima and fully characterized by our 
research group. Their structures are shown in Figure 1.2 and Figure 1.3. 
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Figure 1.2 Core structure of POPs. POPs isolated from M. tenacissima differ by their 
R, Ri and R2 groups, except POP78, POP79, POP80 and P0P81. 
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Figure 1.3 The R, Ri and R2 groups of different POPs isolated from M. tenacissima 
were listed and the whole structure of POP78, POP79, POP80 and P0P81 were 
shown. “ represents novel compounds. 
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1.4 Objectives of Current Study 
As mentioned previously, MDR remains a major obstacle in cancer chemotherapy. 
Although numerous inhibitors the ABC drug transporters have been reported in the 
literature, many of them did not demonstrate benefit to the patients in phase II 
clinical trials or were found to cause severe adverse effects. TCMs are generally 
considered as the fourth generation of ABC drug transporters inhibitor for their 
safety and efficacy. However, many of them have not been studied for their specific 
mechanisms underlying the circumvention of MDR. Moreover, their toxicity and 
interaction with other MDR ABC drug transporters (MRPl and ABCG2) have not 
been investigated. Therefore, a more thorough investigation into potential TCM 
candidates that are potent and safe in treating MDR is badly needed. M. tenacissima 
is a popular TCM used in the Yunan province in China for treating cancer and 
lung-related diseases. While it has been claimed that M. tenacissima can kil l cancer 
cells directly, M. tenacissima has also be proposed to assist other chemotherapeutic 
drugs in treating cancer patients. The underlying mechanisms for the synergistic 
effect of M. tenacissima and other chemotherapeutic drugs in cancer, especially in 
MDR cancer, remain to be studied. 
In this report, we sought to systematically evaluate these POPs in terms of their 
antitumor activity and the potential MDR-reversal activity in cancer cell lines with 
overexpression of various ABC multidrug resistance transporters and to reveal 
important structural determinants for these properties. Currently, studies on 
compounds isolated from Chinese medicine in circumventing P-gp-mediated MDR 
mainly focused in their effectiveness while lacking structure-activity relationship that 
can explain the definitive for P-gp. Besides providing the scientific basis for the 
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reversal of MDR by the POPs, our study also revealed important structural 
determinants for inhibition of P-gp, ABCG2 or MRPl. 
The objectives of the current study are to: 
1. Screen for the compounds isolated from M. tenacissima that are effective to 
reverse P-gp-, MRPl-and/or ABCG2-mediated MDR 
2. Study the structure-activity relationship for P-gp inhibition 
3. Examine the mechanisms of MDR reversal by selected effective compounds 
4. Study the potential biotransformation of abundant ineffective POPs to effective 
POPs in microbiotaintestinal microbiota solution 
5. Evaluate for the in vitro toxicity of selected effective compounds in sensitive 
human breast cancer cells MCF-7 
6. Investigate the in vivo toxicity of various fractions isolated from M. tenacissima. 
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CHAPTER 2. EFFECTS OF POLYOXYPREGNANE 
COMPOUNDS ON VIABILITY AND PROLIFERATION OF 
HUMAN RESISTANT CANCER CELLS 
The stem of Marsdenia tenacissima (M tenacissima) is widely used as Caulis 
Marsdeniae Tenacissimae in Yunnan province in China. Caulis Marsdeniae 
Tenacissimae is an important component in a wide variety of formulations in 
traditional folk medicine and Chinese medicine. 124 Besides treating 
respiratory-related disease, M. tenacissima has also been used in treating cancer 
patients for killing cancer cells directly, facilitating cytotoxic effect of anticancer 
drug, and/or reducing side effects of radiotherapy and chemotherapy. ^^ ^ Moreover, 
M tenacissima has been used in patients suffering different types of cancer, varying 
from gastric carcinoma, liver cancer, esophageal cancer to hepatocellular carcinoma. 
126 127 
，However , the active compounds in M. tenacissima for afore mentioned activity 
are still under investigation. Among compounds identified in M. tenacissima, 
polyoxypregnanc glycoside is the major focus but their contribution in treating 
cancer patient is still largely unknown. In this chapter, polyoxypregnanc 
compounds (POPs) including eleven novel POPs have been isolated from M. 
tenacissima and screened for their cytotoxity towards cancer cells. Furthermore, the 
multidrug resistance reversal effects of POPs were also investigated in ABC drug 
transporters overexpressing cancer cells. 
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2.1 Materials and Methods 
2.1.1 Chemicals, Materials and Reagents 
All of the drugs, chemicals and reagents used were of analytical grade and were 
purchased from the companies listed in the tables below. Al l cell culture labware 
were purchased from TPP®. PSC833 and fumitremorgin C (FTC) were kind gifts 
from Dr Susan Bates (National Cancer Institute, NIH, USA). POPs were isolated 
from M tenacissima by Shanghai Institute of Materia Medica, SIMM, Chinese 
Academy of Sciences. 
Cell Culture/Drugs 
Chemical/Reagent Product Brand Catalog Number 
Doxorubicin HCl Yick-Vic Chemicals PH-1898 
Mitoxantrone dihydrochloride Sigma-Aldrich® M6545 
MK571 Sigma-Aldrich® M7571-25 
Dulbecco's phosphate-buffered saline Gibco® 21600-010 
Fetal bovine serum Biosera S1810 
HEPES Sigma-Aldrich® H4034 
RPMI 1640 medium Gibco® 23400-021/22400-071 
D-MEM medium Gibco® 12430-047 
Penicillin G, sodium salt Sigma-Aldrich® P3032 
Sodium bicarbonate Sigma-Aldrich® S5761 
Streptomycin sulfate Gibco® 11860-03 8 
Trypsin, 0.25% Gibco® 15050-065 
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Sulforhodamine B assay 
Chemical/Reagent Product Brand Catalog Number 
TCA Uni-Chem UC-T59648-41 
SRB (Sulforhodamine B sodium salt) Sigma-Aldrich® S1402 
Acetic Acid LABSCAN PLA00654X 
Tris-base Sigma-Aldrich® T1378 
2.1.2 Methods 
2.1.2.1 Cell Lines and Cell Culture 
Resistant cell lines with defined overexpression of P-gp, MRPl, or ABCG2 were 
used to test for the MDR reversal activity of the POPs. P-gp-overexpressing 
SW620/Ad300i30, MRP-l-overexpressing MCF-7/Vpi3i and ABCG2-overexpressing 
MCF-7/FLV1000132 were generous gift from Dr. Susan Bates from the National 
Cancer Institute (Bethesda, MD, USA). They were resistant sublines developed from 
their parental SW620 or MCF-7 cells, respectively, by stepwise selection in 
increasing concentrations of selecting agent and were currently maintained in 300 
‘uM doxorubicin, 10 ‘uM etoposide and 1000 nM flavopiridol, respectively. The 
resistant cells were grown in drug-free medium for at least 2 weeks before use. In 
these resistant cancer cell line models, overexpression of a single ABC transporter 
was observed upon stepwise drug selection. Moreover, the reversal of drug resistance 
by specific inhibitor against the individual transporter suggests contribution of only 
one transporter to the resistance phenotype in each model. SW620 and 
SW620/Ad300 were cultured in RPMI 1640 supplemented with 10% fetal bovine 
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serum. MCF-7, MCF-7/VP and MCF-7/FLV1000 were cultured in DM EM 
supplemented with 10% fetal bovine serum. Resistant cancer cell lines 
SW620/Ad300, MCF-7/VP and MCF-7/FLV1000 were authenticated by comparing 
the fold resistance with that of the parental drug-sensitive cell lines SW620 or 
MCF-7 respectively and examining the expression level of P-gp, MRPl or ABCG2. 
Al l cells were incubated at 37°C in a humidified atmosphere of 5% CO2. 
2.1.2.2 Preparation of POPs 
The dried stems of M. tenacissima (20.3 kg) were extracted three times with 95% 
ethanol at room temperature for 3 days, which afforded a dark residue (3.4 kg) after 
evaporation of the solvent. The residue was suspended in water and then partitioned 
with ethyl acetate and n-butanol successively to give fractions ethyl acetate (460 g) 
and butanol (500 g), respectively. The part of ethyl acetate layer (270 g) was 
subjected to column chromatography (silica gel, Petroleum ether/ethyl acetate 3:1 ~ 
1:2, 100% ethyl acetate, and then ethyl acetate/methanolmethanol 20:1 〜4:1) to give 
five fractions. Fractions were then recrystallized or subjected to column 
chromatography using different condition to give a series of 30 POPs. Al l isolated 
POPs share the same core structure with differing substituents at R, R!, and R2 
(Figure 1.2 in Chapter 1). The identity and purity of all isolated POPs have been fully 
characterized by ^H- and ^^C-nuclear magnetic resonance (NMR), mass spectrometry 
(MS) and high-performance liquid chromatography (HPLC). 
2.1.2.3 Sulforhodamine B assay 
To determine the effects of POPs of M. tenacissima on the viability of SW620, 
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SW620/Ad300, MCF-7, MCF-7/VP or MCF-7/FLV1000 cells, cell number was 
quantified using the sulforhodamine B (SRB) assay. The SRB assay is based on the 
binding of SRB, an aminoxanthene dye with two sulfonic groups, to proteins of cells 
that have been fixed to tissue-culture plates by tricholoracetic acid.'^^ SRB binds to 
basic amino-acid residues under mild acidic condition and can dissociate under basic 
condition. The amount of SRB dye bound is directly proportional to the cell density 
and the absorbance of the colored solution can be analyzed using a 
spectrophotometer. SRB was prepared in 1% acetic acid to make a 0.4% stock and 
stored at room temperature. Cells were seeded overnight in 96-well plates at a 
density of 6.0 x 10^  cells per well (SW620, SW620/Ad300) or 4.0 x 10^  cells per 
well ( M C F - 7 , M C F - 7 / V P , M C F - 7 / F L V 1 0 0 0 ) with 100 |LIL of culture medium. Cells 
were treated with various concentrations of substrate of anti-cancer drugs, 
doxorubicin (0-800 |LIM) for P-gp and M R P L and mitoxantrone (0-25 j iM) for 
ABCG2, with or without POP for 72 h. Cells were incubated with cold 10% TCA at 
4 for 1 h for fixation and then washed three times with slow-running tap water. 
The plates were allowed to air-dry at room temperature. The cells were then 
incubated with 0.4% SRB at room temperature for 1 h and then washed three times 
with 1% acetic acid to remove unbound dye. The plates were allowed to dry at room 
temperature before the addition of 200 |LIL of 10 mM Tris base solution to dissolve 
the protein-bound dye for absorbance measurement. Signal was measured on 
Benchmark Plus Microplate Spectrophotometer (Bio-Rad, Hercules, CA, US) at a 
wavelength of 570 nm with 45 seconds shaking. The experiment was conducted in 
quadruplicates. The absorbance of the untreated cells in medium was considered 
100%. The concentrations of doxorubicin that reduce cell viability by 50% (IC50 
values) were estimated from sigmoidal dose-response curve fitted by GraphPad 
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Pi'ism 3.0 (GraphPad Software, Inc., San Diego, CA, USA). The activities of POPs in 
sensitizing resistant cancer cells SW620/Ad300, MCF-7/VP and MCF-7/FLV1000 to 
substrate drugs of the three transporters were evaluated by comparing IC50 values of 
substrate drugs in the absence or presence of POP and expressed as % reduction. 
0/0 reduction = [l-{IC5o (anticancer drug with POP in resistant cells) / IC50 (anticancer 
drug without POP in resistant cells)}] xlOO 
The higher the % reduction (maximum - 100), the stronger is the drug sensitization 
effect. PSC833, MRK571 and FTC, known specific inhibitors for P-gp, MRPl and 
ABCG2, respectively, were used as the positive controls in the MDR reversal 
experiments. 
2.1.2.4 Statistical analysis 
Data are expressed as mean value 士 S.EM, from at least three independent 
experiments unless otherwise specifically described. The data were analyzed by 
unpaired t test using GraphPad Prism 3.0. The significance of differences was set at 
户 <0.05. 
2.2 Results 
2.2.1 Effects of POPs on the viability of parental SW620 and 
P-gp-overexpressing resistant SW620/Ad300 cells 
The ability of POPs to circumvent P-gp-mediated MDR toward the substrate 
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anticancer drug doxorubicin was evaluated in a pair of parental SW620 and 
P-gp-overexpressing resistant SW620/Ad300 cells. As shown in Figure 2.1, the 
resistant SW620/Ad300 cells (IC50 = 2 8 . 2 2 士 0.52 [iM) were found to be 166-fold 
more resistant than the parental SW620 cells (IC50 = 0.17 土 0.05 ^iM) to doxorubicin. 
PSC833, a specific P-gp inhibitor, was used as a positive control, which at 400 nM 
abolished the resistance of doxorubicin in resistant SW620/Ad300 cells (IC50 
decreased from 28.22 士 0.52 ^ M to 0.22 士 0.03 |liM). 30 POPs, including 11 novel 
POPs, were screened at 10 [ iM for their effects in enhancing the cytotoxicity of 
doxorubicin in resistant SW620/Ad300 cells and sensitive SW620 cells. The IC50 
values are summarized in Table 2.1 and Table 2.2. The effects of POP63 and POP85 
were shown as representative data of effective POPs and ineffective POPs 
respectively in Figure 2.1. Al l POPs (at 10 pM) did not affect the cytotoxicity of 
doxorubicin in sensitive SW620 cells. POP52, POP53, POP55, POP56, POP62, 
POP63, POP65, POP66, POP86, POP87 and POP88, in which 4 of them were novel 
POPs, were found to effectively reduce doxorubicin IC50 by more than 50% in 
resistant SW620/Ad300 cells (Table 2.1). For these 11 effective POPs, two more 
concentrations, 2 |LIM and 0.4 |LIM, were also tested for their reversal of 
P-gp-mediated MDR using the SRB assay. While POP52, POP53, POP55, POP56, 
POP62, POP63, POP65 and POP87 were found to be effective at 2 |iM, POP55, 
POP56 and POP65 were also found to be effective at 0.4 |aM (Table 2.1). According 
to their effective concentrations and % reduction determined, the potency of the 11 
effective POPs can be arranged as POP55 = POP56 = POP63 = POP65 > 
POP53 » POP52 = POP62 > POP87 » POP66 > POP88 > POP86. For the 19 
ineffective POPs, their IC50 values were summarized in Table 2 . 2 and all their % 
reduction were less than 50%. 
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Figure 2.1 Representative data showing the effects of A) doxorubicin, B) doxorubicin 
with PSC833 (400 nM), C) doxorubicin with effective POP63 (10 ‘uM) and D) 
doxorubicin with ineffective POP85 (10 ‘uM) on the viability of sensitive SW620 and 
resistant SW620/Ad300 cells after 72 h treatment, (n二3) 
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Table 2.1 Cytotoxicity of P-gp substrate anti -cancer drug doxorubicin and reversal of 
P-gp-mediated MDR by effective POPs in SW620/Ad300 
IC50 ± SD ( | l iM ) (0/0 reduction) 
SW62Q SW62Q/Ad300 
Doxorubicin alone 0.17 士 0.05 fO.0%) 28.22 士 0.52 fO.0%) 
Positive control 
+ PSC833 (400 nM) 0.10 士 0.06 (41.2%) 0.22 士 0.03 ( 99 .2%) 
Effective POPs 
+ POP52卞（0.4 uM) 0.12 ±0.11 (-20.0%) 4.46 ± 0.12 (34.：30/0) 
+ POP52卞（2 uM) 0.11 ±0.06(35.30/0) 2.06 ±0.21 f92.7%) 
+ POP52卞 nOuM) 0.22 ± 0.09 (-29.40/0) 0.85 ±0.11 (97.0%) 
+ POP53 (0.4 uM) 0.10 士 0.08 (0.0%) 3.34 土 0.29 (50.9%) 
+ POP53 (2 iiM) 0.16 士 0.08 (5.9%) 6.38 士 0.39 (77.4%) 
+ P O P 5 3 N O U M ) 0.20 士 0 .09 ( - 1 7 . 6 % ) 3 .92 士 0 .41 ( 8 6 . 1 % ) 
+ POP55 (0.4 uM) 0.10 ± 0.08 (-25.O0/0) 1.04 士 0.11 ( 84 .7%) 
+ POP55 (2 uM) 0.16 士 0.05 (5.9%) 1.91 士 0.21 (93.2%) 
+ POP55 (10 uM) 0.21 士 0.06 (23.5%) 1.48 士 0.23 ( 94 .8%) 
+ POP56 (0.4 uM) 0.10 ± 0.14 (0.0%) 0.92 士 0.16 (86.5%) 
+ POP56 (2 uM) 0.10 士 0.07 (-11.1%) 0.90 士 0.09 ( 91 .4%) 
+ POP56 (10 uM) 0.22 土 0.33 (29.0%) 0.60 士 0.06 ( 94 .3%) 
+ POP62 (0.4 iiM) 0.12 士 0.15 (20.0%) 3.52 士 0.07 (20.4%) 
+ POP62 (2 uM) 0.19 士 0.05 (41.2%) 2.09 士 0.21 ( 92 .6%) 
+ POP62 (10 uM) 0.21 士 0.06 (-23.5%) 0.56 士 0.09 (98.0%) 
+ POP63 (0.4 uM) 0.07 士 0.07 (30.0%) 3.18 士 0.12 (53.2%) 
+ POP63 (2 uM) 0.20 士 0.08 (-17.6%) 1.51 士 0.04 (94.6%) 
+ POP63 (10 uM) 0.15 士 0.05 (11.8%) 0.71 士 0.09 ( 97 .5%) 
+ POP65 (0.4 uM) 0.08 士 0.08 (20.0%) 1.66 土 0.09 (75.6%) 
+ POP65 (2 uM) 0.07 士 0.05 (22.2%) 0.89 士 0.05 ( 91 .5%) 
+ POP65 (10 uM) 0.10 ± 0.06 11.10/0) 0.31 士 0.04 (94.2%) 
+ POP66 (0.4 uM) 0.03 士 0.08 (0.0%) 5.42 士 0.27 (20.3%) 
+ POP66 (2 uM) 0.06 士 0.07 (-20.0%) 3.58 士 0.06 (36.9%) 
+ POP66 no uM) 0.25 士 0.26 (19.4%) 0.96 士 0.05 (90.8%) 
+ POP86卞（0.4 iiM) 0.03 士 0.05 (0.0%) 3.19 士 0.05 (27.8%) 
+ POP86卞(2 liU) 0.20 士 0.08 (-17.6%) 16.95 士 1.96 (39.3%) 
+ POP86卞 n o uM) 0.15 士 0.05 (11.8%) 4.95 士 0.39 (82.5%) 
+ POP87卞(0.4 uM) 0.07 士 0.05 (22.2%) 4.55 士 0.06 (22.0%) 
+ POP87卞（2 i iU) 0.09 士 0.06 (31.3%) 13.50 土 0.04 (82.3%) 
+ POP87卞 no uM) 0.10 士 0.08 (28.6%) 0.61 士 0.06 (93.9%) 
+ POP88卞(0.4 uM) 0.09 士 0.07 (0.0%) 0.55 ± 0.17 (21.4%) 
+ POP88卞(2 uM) 0.22 士 0.06 (-29.4%) 15.95 ±2.15 (43.5%) 
_ _ + P O P 8 8 " 1 0 _ ) 0.19 ±0.09 Ml.8%^ 3.49 ± 0.35 
卞 Novel POPs isolated from M. tenacissima. 
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Table 2.2 Cytotoxicity of P-gp substrate anti-cancer drug doxorubicin and reversal of 
P-gp-mediated MDR by ineffective POPs in SW620/Ad300 
IC50 ± SD (|LIM) (0/0 reduction) 
SW620 SW620/Ad300 
Doxorubicin alone 0.17 士 0.05 rO.0%) 28.22 士 0.52 (0.0%) 
Positive control 
+ PSC833 (400 nM) 0.10 士 0.06 (41.2%) 0.22 士 0.03 (99.2%) 
Ineffective POPs 
+ POP64 (10 uM) 0.15 士 0.04 (11.8%) 18.10 士 0.32 (35.9%) 
+ POP68 (10 uM) 0.21 士 0.32 (34.4%) 5.50 土 0.09 (-2.4%) 
+ POP69 n o uM) 0.12 ± 0.11 (14.3%) 7.95 土 0.25 (20.0%) 
+ POP70 (10 uM) 0.10 士 0.06 (41.2%) 3.11 土 0.03 (42.1%) 
+ P0P71 n o uM) 0.16 士 0.08 (5.9%) 12.50 士 0.44 (55 7%) 
+ POP72 n o uM) 0.17 士 0.07 (0.0%) 38.40 土 1.35 (-36.1%) 
+ POP73卞 n o uM) 0.18 士 0.06 (-5.9%) 17.10 士 0.52 (39.4%) 
+ POP74卞no uM) 0.21 士 0.14 (34.4%) 5.58 士 0.07 f-3.9%) 
+ POP75卞no uM) 0.33 士 0.12 (23.3%) 4.93 士 0.05 (-38.9%) 
+ POP76卞 n O u M ) 0.12 ±0.05 (29.4%) 18.97 ±0.41 (32.8%) 
+ POP77卞 n o uM) 0.62 土 0.21 (-44.2%) 7.21 ± 0.18 (27.5%) 
+ POP78 (10 uM) 0.17 士 0.04 (0.0%) 17.08 士 0.53 (39.5%) 
+ POP79 flO uM) 0.15 士 0.08 f l l .8%) 21.42 士 0.43 (24.1%) 
+ POP80 n o uM) 0.18 士 0.10 f-5.9%) 23.88 士 1.32 (15.4%) 
+ P0P81 卞 n o uM) 0.14 土 0.03 (17.6%) 23.93 士 0.61 (15.2%) 
+ POP82卞 n o uM) 0.16 士 0.06 (5.9%) 19.03 士 1.76 (32.6%) 
+ POP83 (10 uM) 0.18 士 0.04 f-5.9%) 28.86 士 1.52 (-2.3%) 
+ POP84 n o uM) 0.15 士 0.07 (11.8%) 24.52 士 1.98 (13.11%) 
~ + P Q P 8 5 ( 1 Q ^ M ) 0.17 ±0.05 ro.0%^ 22.60 ± 1.12 n9.91o/o) 
^ Novel POPs isolated from M. tenacissima. 
2.2.2 Effects of POPs on the viability of parental MCF-7 and 
MRPl-overexpressing resistant MCF-7/VP cells 
Similar to section 2.2.1, the reversal of MRP 1-mediated MDR by the 30 POPs was 
evaluated in another pair of parental MCF-7 cells and drug selected 
MRPl-overexpressing resistant MCF-7/VP cells. Doxorubicin, being also a MRPl 
substrate anti-cancer drug, was used in the screening. As shown in Figure 2.2, 
doxorubicin dose-dependently reduced cell viability and its IC50 values were 0.22 士 
’ � 
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0.06 |LIM ill sensitive MCF-7 cells and 2.48 士 0.33 |LIM in resistant MCF-7/VP cells. A 
specific MRPl inhibitor, MK571, was used as the positive control. At 40 ‘uM, 
MK571 significantly reduced doxorubicin IC50 from 2.48 士 0.33 |LIM to 0.18 土 0.04 
|LIM in resistant MCF-7/VP cells. 30 POPs, including 11 novel POPs, were screened 
at 10 \iM for their effects in enhancing the cytotoxicity of doxorubicin in resistant 
MCF-7/VP cells and parental MCF-7 cells. The effects of POP65 and POP74 were 
shown as representative data of effective POPs and ineffective POPs respectively in 
Figure 2.2. The results are summarized in Table 2.3 and Table 2.4. A l l POPs, at 10 
‘uM, showed no enhancement of cytotoxicity of doxorubicin in sensitive MCF-7 cells. 
However, POP53, POP55, POP63, POP65, POP86 and POP87 (2 of which are novel 
POPs) were found to effectively reduce the doxorubicin IC50 by more than 50% in 
the resistant MCF-7/VP cells (Table 2.3). These 6 effective POPs were also tested at 
2 |iM, where POP55 was also found to be effective (Table 2.3). Considering the 
reversal effect of these 6 effective POPs, their potency order from highest to lowest 
is POP55 » POP65 > POP87 > POP53 > POP86 > POP63. For other ineffective 24 
POPs, their IC50 values were summarized in Table 2.4 and all their % reduction were 
lower than 50%. 
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Figure 2.2 Representative data showing the effects of A) doxorubicin, B) doxorubicin 
with probenecid (500 pM), C) doxorubicin with effective POP65 (10 ‘uM) and D) 
doxorubicin with ineffective POP74 (10 pM) on the viability of sensitive MCF-7 and 
resistant MCF-7/VP cells after 72 h treatment. (n=3) 
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Table 2.3 Cytotoxicity of MRPl substrate anti-cancer drug doxorubicin and reversal 
of MRPl-mediated MDR by effective POPs in MCF-7/VP 
IC50 ± SD (|iM) (0/0 reduction) 
MCF-7 MCF-7/VP 
Doxorubicin alone 0.22 士 0.06 rO.0%) 2.48 士 0.33 fO.0%) 
Positive control 
+ MK571 (40 uM) 0.22 士 0.07 (0.0%) 0.18 士 0.04 ( 92 .7%) 
Effective POPs 
+ POP53 (2 uM) 0.24 士 0.08 (-9.1%) 1.55 士 0.15 (37.5%) 
+ POP53 (10 uM) 0.22 士 0.09 (0.0%) 0.99 ±0.13 (60.1%) 
+ P O P 5 5 (2 \iM) 0.21 士 0.05 (4.5%) 0.92 士 0.21 ( 6 2 . 9 % ) 
+ POP55 (10 uM) 0.21 士 0.06 (4.5%) 0.53 ±0.11 (78.6%) 
+ POP63 (2 uM) 0.20 士 0.08 (9.1%) 1.56 士 0.04 (37.1%) 
+ POP63 (10 uM) 0.20 士 0.05 (9.1%) 1.22 士 0.09 ( 50 .8%) 
+ POP65 (2 uM) 0.64 土 0.04 (-6.7%) 1.12 士 0.07 (0.0%) 
+ POP65 n o nM) 0.09 士 0.03 (10.0%) 0.33 士 0.14 (70.5%) 
+ POP86卞(2 uM) 0.22 士 0.06 (0.0%) 1.75 ± 0.16 (29.4%) 
+ POP86卞(10 uM) 0.22 士 0.09 (0.0%) 1.14 ± 0.14 ( 5 4 . 0 % ) 
+ POP87卞(2 m ) 0.54 士 0.05 (10.0%) 0.6 士 0.02 (45.5%) 
_ _ _ + POP87卞 N O U M ) 0.33 士 0.03 (2 .9%^ 0.4 士 0 .04 R69.0%^ 
t Novel POPs isolated from M. tenacissima. 
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Table 2.4 Cytotoxicity of MRPl substrate anti-cancer drug doxorubicin and reversal 
of MRPl-mediated MDR by ineffective POPs in MCF-7/VP 
IC50 ± S D (|liM) (0/0 reduction) 
MCF-7 MCF-7/VP 
Doxorubicin alone 0.22 士 0.06 (0.0%^ 2.48 士 0.33 rO.0%) 
Positive control 
+ MK571 (40 uM) 0.22 士 0.07 (0.0%) 0.18 士 0.04 (92.7%) 
Ineffective POPs 
+ POP52^ n o uM) 0.20 士 0.09 (9.1%) 2.19 士 0.31 (11.7%) 
+ POP56 (10 uM) 0.10 士 0.05 (0.0%) 0.74 士 0.07 (34.0%) 
+ POP62 n o uM) 0.21 士 0.04 (4.5%) 2.81 土 0.32 (-13.3%) 
+ POP64 (10 uM) 0.23 士 0.08 (-4.5%) 2.36 士 0.22 (4.8%) 
+ POP66 n o uM) 0.36 士 0.03 (0.0%) 0.85 士 0.02 (0.0%) 
+ POP68 (10 ixM) 0.08 士 0.04 (20.0%) 1.06 士 0.17 (5.4%) 
+ POP69 (10 uM) 0.08 士 0.04 (20.0%) 0.37 士 0.08 (30.2%) 
+ P O P 7 0 ( 1 0 U M ) 0.11 ± 0 . 0 4 (-IO.O0/0) 1.04 ± 0 . 0 9 (31.10/0) 
+ P0P71 (10 uM) 0.25 士 0.09 (-13.6%) 2.59 士 0.41 (-4.4%) 
+ POP72 n o uM) 0.21 士 0.07 (4.5%) 2.39 士 0.18 (3.6%) 
+ POP73t (10 uM) 0.22 士 0.06 (0.0%) 2.45 士 0.25 (1.2%) 
+ POP74"^nO uM) 0.11 ±0.05 (-10%) 0.34 ± 0.16 (35.80/0) 
+ POP75^ n o uM) 0.10 士 0.05 (0.0%) 0.37 士 0.08 (30.2%) 
+ POP76^ (10 uM) 0.18 士 0.05 (18.2%) 2.87 士 0.52 (-15.7%) 
+ POP77^ (10 uM) 0.27 士 0.04 (-17.4%) 1.37 士 0.03 (6.8%) 
+ POP78 (10 uM) 0.21 士 0.04 (4.5%) 2.85 士 0.41 (-14.9%) 
+ POP79 n o iiM) 0.26 士 0.09 (-18.2%) 2.59 士 0.28 (-4.4%) 
+ POP80 n o uM) 0.24 士 0.05 f-9.1%) 2.44 ± 0.23 (1.6%) 
+ P0P81^ (10 uM) 0.20 士 0.03 (9.1%) 2.08 士 0.09 fl6.1%) 
+ POP82^ n o uM) 0.24 士 0.06 (-9.1%) 2.36 士 0.32 (4.8%) 
+ POP83 (10 nM) 0.20 士 0.04 (9.1%) 2.62 士 0.41 (-5.6%) 
+ POP84 n o iiM) 0.24 士 0.07 (-9.1%) 2.51 士 0.43 (-12%) 
+ POP85 n o uM) 0.24 士 0.05 (-9.1%) 2.42 士 0.51 (2.4%) 
+ POP88"10 uM) 0.18 ±0.02 (18.20/0) 2.31 ±0.41 (6.9%) 
t Novel POPs isolated from M. tenacissima. 
2.2.3 Effects of POPs on the viability of parental MCF-7 and 
ABCG2-overexpressing resistant MCF-7/FLV1000 cells 
The 30 POPs isolated from M. tenacissima were also tested for their potential 
circumvention of ABCG2-mediated MDR using a pair of parental MCF-7 and its 
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drug selected ABCG2-overexpressing MCF-7/FLV1000 cells. Mitoxantrone, a 
commonly used ABCG2 substrate anti-cancer drug, was used in this assay. As shown 
in Figure 2.3, mitoxantrone dose-dependently reduced cell viability and its IC50 
values was 0.0052 士 0.0021 |aM in sensitive MCF-7 cells and 1.81 士 0.32 in 
resistant MCF-7/FLV1000 cells. FTC, a specific ABCG2 inhibitor, was used as a 
positive control at 5 ‘uM to significantly enhance the cytotoxicity of mitoxantrone 
with the IC50 value 0 .029 士 0 .005 |LIM in resistant M C F - 7 / F L V 1 0 0 0 cells. 30 POPs, 
including 11 novel POPs, were screened at 10 | iM for their effects in enhancing the 
cytotoxicity of mitoxantrone in resistant MCF-7/FLV1000 cells and sensitive MCF-7 
cells and the IC50 values are summarized in Table 2.5 and Table 2.6. The effects of 
POP65 and POP68 were shown as representative data of effective POPs and 
ineffective POPs respectively in Figure 2.3. Al l POPs, at 10 ‘uM，did not affect the 
cytotoxicity of mitoxantrone in sensitive MCF-7 cells. POP65, POP86 and POP87 (at 
10 pM), in which the latter two are novel POPs, were found to significantly lower the 
IC50 value of mitoxantrone by more than 50% and were considered effective to 
circumvent the ABCG2-mediated MDR (Table 2.5). These 3 effective POPs were 
also tested at 2 |LIM but were found to have % reduction lower than 50% (Table 2.5). 
While the potencies of the 3 effective POPs are generally comparable, POP86 
demonstrated a slightly higher % reduction at 10 |LIM. For the remaining 27 
ineffective POPs, their IC50 values were summarized in Table 2.6 and all their % 
reduction were lower than 50%. 
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Figure 2.3 Representative data showing the effects of A) mitoxantrone, B) 
mitoxantrone with FTC (5 ‘uM), C) mitoxantrone with effective POP65 (10 pM) and 
D) mitoxantrone with ineffective POP68 (10 ‘uM) on the viability of sensitive MCF-7 
and resistant MCF-7/FLV1000 cells after 72 h treatment. (n=3) 
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Table 2.5 Cytotoxicity of ABCG2 substrate anti-cancer drug mitoxantronc and 
reversal of ABCG2-mediated MDR by effective POPs in MCF-7/FLV1000 
IC50 士 SD (|LIM) (0/0 reduction) 
— MCF-7 MCF-7/FLV1Q0Q 
Mitoxantrone alone 0.0100 士 0.0752 rO.0%) 1.04 ± 0.10 rO.0%) 
Positive control 
+ FTC (5 i iM) 0.0117 ± 0.1235 (-I7.O0/0) 0.022 ± 1.103 ( 9 7 . 9 % ) 
Effective POPs 
+ POP65 (2 uM) 0.0071 士 0.0661 (29.0%) 1.20 士 0.09 (-15.4%) 
+ POP65 (10 uM) 0.0076 士 0.0741 (24.0%) 0.30 ±0.17 (71.2%) 
+ POP86^ (2 i iM) 0.0113 士 0.1211 (-13.0%) 0.68 士 0.12 (34.6o/o) 
+ POP86卞 n o uM) 0.0080 ± 0.0467 (2O.O0/0) 0.29 ±0.11 ( 7 2 . 1 % ) 
+ POP87卞(2 uM) 0.0108 士 0.0647 (-8.0%) 0.51 士 0.10 (51.0%) 
_ + P O P 8 7 " 1 0 uM、 0.0086 士 0.0982 04.0%) 0.30 ± 0.15 ( 7 1 . 2 % ) 
卞 Novel POPs isolated from M. tenacissima. 
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Table 2.6 Cytotoxicity of ABCG2 substrate anti-cancer drug mitoxantrone and 
reversal of ABCG2-mediated MDR by ineffective POPs in MCF-7/FLV1000 
IC50 ± SD (|iM) (0/0 reduction) 
MCF-7 MCF-7/FLV1QQQ 
Mitoxantrone alone 0.0052 士 0.0021 rO.0%) 1.81 士 0.32 H.OO) 
Positive control 
+ FTC (5 uM) 0.0047 士 0.0024 (9.6%) 0.029 士 0.005 (98.4%) 
Ineffective POPs 
+ POP52^ (10 uM) 0.0130 士 0.0091 (-150.0%) 2.11 士 0.35 (-16.6%) 
+ POP53 n o uM) 0.0092 士 0.0082 (-76.9%) 2.15 士 0.44 (-18.8%) 
+ POP55 n o uM) 0.0087 士 0.0073 (-67.3%) 1.88 士 0.35 f-3.9%) 
+ POP56 (10 uM) 0.0134 士 0.0095 (-157.7%) 1.45 士 0.54 (19.8%) 
+ POP62 (10 uM) 0.0048 士 0.0060 (7.7%) 2.22 士 0.52 (-22.7%) 
+ POP63 (10 uM) 0.0150 士 0.0042 (-188.5%) 1.64 士 0.32 (9.4%) 
+ POP64 (10 uM) 0.0064 士 0.0032 (-23.0%) 2.51 士 0.44 (-38.7%) 
+ POP66 (10 uM) 0.0073 ±0.0047 (-40.4%) 2.60 士 0.63 (-43.6%) 
+ POP68 (10 uM) 0.0094 士 0.0778 (6.0%) 1.37 士 0.07 (-31.7%) 
+ POP69(10 uM) 0.0111 士 0.0687 Ml.Qo/o) 1.73 ±0.11 (-663%) 
+ POP70 (10 uM) 0.0077 士 0.0896 (23.0%) 1.22 士 0.08 (-17.3%) 
+ P0P71 (10 uM) 0.0191 士 0.0083 (-267.3%) 2.41 士 0.54 (-33.1%) 
+ POP72flO uM) 0.0050 ± 0.0024 a8o/o) 2.01 ± 0.26 (-1 l.Oo/o) 
+ POP73^ n o uM) 0.0056 士 0.0036 (-7.7%) 1.96 土 0.41 (-8.3%) 
+ POP74^ n o uM) 0.0081 士 0.0065 f-55.8%) 2.45 士 0.39 (-35.4%) 
+ POP75^ (10 uM) 0.0074 士 0.0656 (26.0%) 1.45 ± 0.10 (-39.4%) 
+ POP76^ (10 uM) 0.0090 士 0.0041 (-73.1%) 1.59 士 0.51 (12.2%) 
+ POP77^ (10 uM) 0.0095 士 0.0067 (-82.7%) 2.78 士 0.72 (-53.6%) 
+ POP78 n o uM) 0.0050 士 0.0039 (3.8%) 1.94 士 0.53 (-7.2%) 
+ POP79 n o uM) 0.0121 士 0.0081 (-132.7%) 2.31 士 0.43 (-27.6%) 
+ POP80 n o uM) 0.0109 士 0.0042 (-99.0%) 2.15 士 0.41 (-18.8%) 
+ P0P81^ (10 liM) 0.0150 士 0.0039 (-188.5%) 1.64 士 0.61 (9.4%) 
+ POP82^ n o uM) 0.0101 士 0.0081 (-94.2%) 2.48 士 0.52 (-37.0%) 
+ POP83 n o uM) 0.0081 士 0.0041 (-55.8%) 1.95 士 0.52 (-7.7%) 
+ POP84 (10 iiM) 0.0094 士 0.0050 (-80.8%) 1.78 士 0.42 (1.7%) 
+ POP85(10uM) 0.0117 士 0.0081 (-125.0%) 2.08 ± 0.62 (-14.9o/o) 
+ POP88"10 uM) 0.0123 士 0.0041 (-136.5%) 1.69 士 0.32 (6.6%) 
t Novel POPs isolated from M. tenacissima. 
2.3 Discussion 
ABC transporters, including P-gp, MRPl and ABCG2 play major role in MDR by 
actively extruding anti-cancer chemotherapeutics out of the cells. The results of this 
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Study showed that several POPs are effective in circumventing P-gp-, MRP-] - or 
ABCG2-mediated MDR individually. Among the 30 POPs isolated from M. 
tenacissima, POP52, POP53, POP55, POP56, POP62, POP63, POP65, POP66, 
POP86, POP87 and POP88 were found to be effective in circumventing 
P-gp-mediated MDR at 10 [iM. Interestingly, among these P-gp-targeting POPs, 
POP53, POP55, POP63, POP65，POP86 and POP87 were also found to be effective 
in circumventing MRP 1-medaited MDR. More intriguingly, POP65 and two other 
novel POP86 and POP87 were found to be effective in all three resistant cell lines 
SW620/Ad300, MCF-7/VP and MCF-7/FLV1000, suggesting that they are effective 
in circumventing MDR via multi-targets, including P-gp-, MRPl- and ABCG2-
efflux transporters. MDR is generally caused by multifactorial mechanisms. Very 
often, the resulting MDR phenomenon is not solely developed through 
1 ^ 1 O 
overexpression of a single ABC transporter. ， The capability to circumvent more 
than one ABC transporter-mediated MDR, POP65, POP86 and POP87 are expected 
to have a greater potential to be further developed into useful chemosensitizers. In 
addition, combining the effective POPs (e.g. POP65, POP86 and POP87) may result 
in synergistic effect and further maximize the MDR reversal activity. Therefore, 
mechanisms underlying the modulation of P-gp-, MRPl- and ABCG2-mediated 
MDR by the effective individual and combined POPs are worth further investigation. 
Mechanism underlying the modulation of P-gp-, MRP-1- and ABCG2-mediated 
MDR by the effective POPs should be further investigated. By combining the 
effective POPs (e.g. POP65, POP86 and POP87), synergistic effect may be obtained 
to further maximize the MDR reversal activity. 
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Table 2.7 A summary table associating the structures of effective POPs and their 
MDR reversal effects towards P-gp, MRPl and ABCG2. 
POP R R,丨 R2 P-gp MRP1 ABCG2 
CM, CH】O CH, 0 
65 " 。 窄 c h ’ K CH,->-< “ / v/ 
OH, CHJ 〜 Q 
86" H 々 令 产 ？ J - - < 。 丫 。 Z ^ 
CH 
k f _ _ 」 
C H . , 0 0 \ C H j 
5 3 H c j H Y z z X 
55 H C K 。丫 z z X 
CHy O O r u , 
63 H 。 货 产 ' 。 （ X Y ‘ ‘ X 
OCHJ ^ 
CH, O Ov >CH3 
5 2 " o 二 。 ： Y Z X X 
CM, ,0 /CHj 
5 6 H Y ^ X X 
6 2 冷 卢 〜 Y " ^ X X 
CH, O 0、v_ .CHj 
66 - 兮 S^、'。 CH, 乂 Y ^ X X 
K > - 、 CM, C H OH 广w n . C H , 
8 8 " 旧 岭 资 <。 CHX^ Y Z X X 
HO OH ‘ CH CH, O CH,~‘ \ ' , 、 OCH, ‘ 
2.3.1 Structure activity relationship (SAR) 
A number of POPs isolated from M. tenacissima were found to sensitize P-gp, MRPl, 
or ABCG2-overexpressing resistant cancer cell lines to the respective substrate 
anticancer drugs, suggesting inhibition of the transporters. By screening for effective 
MDR reversing POPs in the cytotoxicity assay, some structure-activity relationship 
requirement for the circumvention of MDR could be generalized. It was observed 
that a hydrogen bond acceptor, acetyl group, at the R2 position was essential for 
inhibition of all of the three transporters. On the other hand, the presence of a 
43 
Chapter 3. Median ism of nine selected polyoxypregnane coiiipoiiiids 
hydrogen bond donor OH group at the R2 position in POP72, POP73, POP74, 1)01)75, 
POP76 and POP77 could render them unable to modulate drug sensitivity in all three 
resistant cancer cell lines. In addition, the sugar moiety at R position should not 
exceed two pyranoses, or it has to be in open chain structure (POP88). For POP68, 
POP69, POP70, POP82, POP84 and POP85, the cyclic three-pyranose sugar moiety 
at the R position apparently made them ineffective in modulating the sensitivity 
towards the substrate drugs of all three transporters. Among all POPs, POP65, 
POP86 and POP87 were found to circumvent MDR mediated by all three MDR 
transporters. A closer look at the structural feature of POP65 revealed that it has 
methyl isobutenyl groups at both Ri and R2 positions and a two-pyranose sugar 
moiety at the R position. POP65 showed the highest potency in modulating all three 
transporters in the series with comparable activity (at 10 ^iM) to the control inhibitors 
in all three resistant cancer cell lines. In fact，it was observed that POP65 had a 
greater modulating effect than POP87 and POP86 generally in all three ABC drug 
transporters, while POP87, having a methyl isobutyl group at Ri position, showed a 
greater reversal effect than having a methyl isobutenyl group at Ri position (POP86). 
The SAR requirement for the inhibition of individual transporters can be further 
explored. For the modulation of MRPl, the substituent at R position can be a 
hydroxyl group or a sugar moiety with up to two pyranoses, either in open chain or 
cyclic form, and a methyl isobutyl, a benzoyl, or a methyl isobutenyl group at the Ri 
position. Once again, an acetyl group at R2 position appears important. However, 
considering POP64, an acetyl substituent at Ri appears to have diminished the P-gp 
and MRPl modulating effects, regardless of the presence of the essential acetyl 
group at R2. The constituents at R and Ri may be important to determine the MRPl 
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modulating activity. A change of the hydroxyl group at the R position in POP53 to a 
carbonyl group (in POP52) or a sugar moiety with two pyranoses structure (in 
POP62) was found to dramatically decrease the MRPl modulating activity. On the 
other hand, when a three-pyranose sugar moiety (POP88) replaced two-pyranose 
sugar moiety (POP86) at the R position, the MRPl modulating activity was found to 
be decreased significantly. 
In modulating P-gp-mediated MDR, POPs should have a benzoyl, methyl isobutyl, 
or methyl isobutenyl group at Ri position but not an acetyl group (POP64). On the 
other hand, the substituent at the R position can be a carbonyl, hydroxyl, or a sugar 
moiety with up to two pyranose structures or a three pyranose structure in open chain 
form. 
As mentioned above, although the presence of an acetyl group at the R2 position 
appeared to be a pre-requisite for inhibition of all three MDR transporters, the 
substituent at the R position could affect whether the resulting POP is effective. For 
example, in the following POPs where there is a cyclic three-pyranose sugar moiety 
(POP68, POP69 and POP70) or four-pyranose sugar moiety (POP82, POP84 and 
POP85) at the R position, they were found to be ineffective in circumventing 
P-gp-mediated MDR despite the presence of an acetyl group at the R2 position. 
Limited information is available about the structural requirements for the inhibition 
of P-gp, ABCG2, and MRPl though some information has been derived from 
scattered observations for individual compounds and structurally unrelated 
a n a l o g u e s . 134J35 jg commonly accepted that substrates/inhibitors of P-gp and 
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ABCG2 are generally of a lipophilic nature and contain hydrogen bond acceptors or 
1 )厂 
basic functionalities. For the inhibition of MRPl, both lipophilic cationic 
compounds and relatively hydrophilic and often negatively charged compounds have 
13 *7 
been reported. These results probably explain why an acetyl group (as a hydrogen 
bond acceptor) at the R2 position in our novel POP series is important for the 
modulation of the three ABC transporters. 
Specific modulators of ABC transporters are desired as pharmacological tools for the 
functional analysis and characterization of various transporters. Beside some putative 
specific P-gp inhibitors (POP52, POP56, POP62, POP66 & POP88), we have also 
identified POP65, POP86 and POP87 as potential broad spectrum inhibitors against 
all three MDR transporters. In fact, the overlapping substrate specificity of different 
ABC transporters may explain why the reversal of MDR by inhibition of one of these 
1 0 0 1 OQ 
transporters often fails in the clinic. ’ Only a few broad spectrum inhibitors of 
these ABC transporters, such as VX-710 (biricodar), have been reported.！斗^ They 
have been used in acute myeloid leukaemia, where constitutive overexpression of the 
three MDR transporters was found to contribute to anticancer drug resistance, and 
overcoming drug delivery problems at the blood-brain barrier or along the 
gastrointestinal tract. 
2.3.2 Nine compounds relating to P-gp-mediated MDR 
In the screening study, 11 POPs isolated from M. tenacissima were found to be 
effective in circumventing P-gp-mediated MDR, in which 9 of them can be 
subdivided into three groups (POP53-POP62-POP68, POP55-POP63-POP69 and 
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POP56-POP66-POP70) as shown in Figure 2.2. Among the effective POPs, POP53, 
POP55 and POP56 differ by their R, groups and POP62, POP63 and POP66 also 
differ by their Ri groups. Interestingly, replacing the hydroxyl group at the R position 
of POP53, POP55 and POP56 by two-pyranose sugar moiety gives POP62, POP63 
and POP66 respectively. Al l these 6 POPs are effective in modulating P-gp 
transporter. While POP68, POP69 and POP70, with three-pyranose sugar moiety 
groups at the R position, were not effective in modulating P-gp transporter in vitro. 
The chemical structures and their potential biotransformation of these 9 POPs in the 
body via metabolic biotransformation are suspected as shown in Figure 2.2. For 
POP53-POP62-POP68 pair, POP68 can be converted to MRPl and P-gp inhibitor 
POP53 and/or P-gp inhibitor POP62. For POP55-POP63-POP69 pair, POP69 can be 
converted to MRPl and P-gp inhibitors POP55 and/or POP63. Similarly, 
POP56-POP66-POP70, POP70 can be converted to P-gp inhibitors POP56 and/or 
POP66. 
It is noteworthy that, POP68, POP69 and POP70 are apparently the most abundant 
POPs in M. tenacissima and accounting for approximately 53.6% in the herbal 
extract, as shown in the chromatogram in Figure 2.3, yet they were found to be 
ineffective in circumventing P-gp-mediated MDR in vitro. 
Hydrolysis often occurs during drug metabolism by enzymes such as glycoside 
hydrolases, thereby resulting in converting glycosides to a g l y c o n e s . ^ Therefore, 
upon the oral administration of the crude extract of M. tenacissima or a composition 
consisting POP68, POP69 and/or POP70, it is hypothesized that POP68 may be 
converted sequentially to POP62 and then POP53, whereas POP69 and POP70 may 
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be converted sequentially to POP63-then-POP55 and POP66-then-POP56 
respectively as shown in Figure 2.2. The significance of this biotransformation is that 
ineffective POPs (i.e. POP68, POP69 and POP70) could be metabolized into 
effective POPs (including POP62, POOP53, POP63, POP55, POP66 and POP56) 
after their oral administration, which is akin to the activation of prodrugs. Therefore, 
these 9 POPs were selected for further studies as described below. Furthermore, the 
investigation on their metabolism biotransformation was conducted to prove our 
hypothesis and the study in this regard is described in Chapter 4. 
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Figure 2.4 Potential biotransformation of three pairs of POPs. 
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Figure 2.5HPLC chromatogram of POP68, POP69 and POP70 in the crude extract of 
M tenacissima. 
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CHAPTER 3. MECHANISM OF NINE SELECTED POPS IN 
MODULATING P-GP-MEDIATED MDR 
The screening of 30 POPs isolated from M. tenacissima for their MDR reversal 
effect on cells overexpressing P-gp, MRPl or ABCG2 have been described in the 
previous chapter. Little was known as to which the active component(s) in M. 
tenacissima are responsible for the chemotherapeutic enhancing effect. Recently, two 
derivatives of POPs (POP55 and POP66) isolated from M. tenacissima have been 
reported to increase drug sensitivity in P-gp-overexpressing human hepatoma cells 
and the mechanism for POP66 has been suggested to be direct interaction with P-gp 
substrate binding site(s).^^^ TCMs studied for MDR reversal effect often focus on the 
modulation on P-gp expression at mRNA and/or protein level without further 
investigation into the m e c h a n i s m . i42 i n Chapter 2, 9 POPs isolated from M. 
tenacissima have been selected for their potential biotransformation in the intestine. 
As POP68, POP69 and POP70 are the three predominant POPs found in the extract 
of M. tenacissima, their potential biotransformation to the effective POPs (namely 
POP53 and/or POP62, POP55 and/or POP63 and POP56 and/or POP66，respectively) 
may account for the MDR reversal effect of the extract in treating cancer patients. In 
this chapter, the investigation into these 9 POPs, especially the underlying 
mechanism of the six effective POPs in modulating P-gp, is described. The three 
most abundant POPs (POP68, POP69 and POP70) yet ineffective in vitro, were also 
tested and they were found to have no interaction with P-gp. 
3.1 Materials and Methods 
3.1.1 Chemicals, Materials and Reagents 
Only materials and reagents that were not mentioned previously in Chapter 2 are 
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described in detail in this section. 
Ceil Culture/Drugs 
Chemical/Reagent Product Brand Catalog Number 
Rhodamine-123 Sigma-Aldrich® R8004 
Minimum essential medium (MEM) Gibco® 41500-034/11095-080 
MEM Non-Essential Amino Acids Gibco® 11140-050 
(NEAA) 
RPMI 1640 medium (phenol red free Gibco® 11835-030 
medium) 
Flow Cytometry 
Chemical/Reagent/Equipment Product Brand Catalog Number 
Flow Cytometer BD Biosciences BD LSRFortessa 
Caco-2 Monolayer Transport Assay 
- *I 
Chemical/Reagent/Equipment Product Brand Catalog Number 
Voltohmmeter World Precision Epithelial Tissue 
Instrments Voltohmmeter 
(EVOM) 
Hanks' Balanced Salt Solution (HBSS) Gibco® 14175-079 
Magnesium Chloride BDH® 101494V 
Calcium Chloride BDH® 1007041 
Microplate Analyzer Packard FUSION Microplate 
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Biosciences Analyzer 
P-gp ATPase Assay 
Chemical/Reagent/Equipment Product Brand Catalog Number 
Pgp-Glo(TM) Assay System with Promega V3601 
P-glycoprotein 
Luminescence Analyzer Perkin-Elmer Wallace Victor〗1420 
Multilabel counter 
Immuno-blot/Western Blot 
Chemical/Reagent/Equipment Product Brand Catalog Number 
40% Acrylamide solution Bio-Rad 161-0141 
p-Actin rabbit monoclonal antibody Cell-Signaling 4970 
Technology® 
Albumin from bovine serum (BSA) Sigma-Aldrich® A2153 
Ammonium persulfate (APS) Bio-Rad 161 -0700 
Anti-mouse IgG, HRP-linked antibody Cell-Signaling 7076 
Technology® 
Anti-rabbit IgG, HRP-linked antibody Cell-Signaling 7074 
Technology® 
2% Bis solution Bio-Rad 161-0143 
Blotting-grade non-fat dry milk Bio-Rad 170-6404 
Bromophenol blue Sigma-Aldrich® BO 126 
P-gp (C219) mouse monoclonal Signet SIG-38710-1000 
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antibody Laboratories, Inc. 
a-Cholic acid Sigma-Aldrich® C1129 
Complete mini EDTA-free protease Roche Applied 11836170001 
inhibitor cocktail tablets Science 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich® E6758 
Filter paper Whatman 3030-392 
Glycerol Sigma-Aldrich® G5516 
H y b o n d ™ ECL™ nitrocellulose Amersham/GE RPN303D 
membrane Healthcare 
20X LumiGLO® reagent and 20X Cell-Signaling 7003 
peroxide Technology® 
2-Mercaptoethanol Sigma-Aldrich® M3148 
Methanol Merck 1.06007.2500 
Mini-Trans Blot Electrophoretic Bio-Rad 170-3930 
Transfer Cell 
Molecular Imager ChemiDocXRS+ Bio-Rad 170-8265 
System 
PowerPac HC Power Supply Bio-Rad 164-5052 
Protein assay dye reagent concentrate Bio-Rad 500-0006 
SeeBlue Plus2 pre-stained standard Invitrogen^^ LC5925 
N,N,N' ,N" -Tetramethylethylenediamine Bio-Rad 161-0801 
(TEMED) 
1 OX Tris/glycine Bio-Rad 161 -0771 
1 OX Tris/glycine/SDS Bio-Rad 161 -0772 
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Triton X-100 Sigma-Aldrich® T8787 
Tween-20 Bio-Rad 170-6531 
Preparation of Specific Buffers for Immuno-blotAVestern Blot 
Buffer Reagents needed 
Radioimmunoprecipitation assay (RIPA) 0.5% a-Cholic acid, 2mM EDTA, 10% 
buffer Glycerol, 150 mM NaCl, 0.1% SDS, 50 
mM Tris (pH 7.5), 1% Triton X-100, 
Distilled water to make up volume 
4X Sample buffer 0.02% Bromophenol blue, 30% Glycerol, 
10% (3-Mercaptoethanol, 0.25M Tris-HCl 
(pH 6.8), 8% SDS, Distilled water to make 
up remaining volume 
Stripping buffer (500 ml) 10 g SDS, 3.786 g Sigma 7-9® (pH 6.7) 
IXTGSand IX TG Dilute lOX stock solution with distilled 
water 
5% Non-fat dry milk Dissolve with IX washing buffer 
IX Washing buffer 100 mM NaCl, 10 mM Tris (pH 7.5), 0.1% 
Tween-20 
3.1.2 Methods 
3.1.2.1 Cell Lines and Cell Culture 
In addition to SW620, SW620/Ad300 and MCF-7 cells, MDRl transfected cells 
HEK293 MDRl and control vector pcDNA3 transfected cells HEK293 pcDNA3 
were used in this study. HEK293 MDRl and HEK293 pcDNA3 cell lines were 
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kindly provided by Dr. Susan Bates (National Cancer Institute, USA). HBK293 
MDRl and HEK293 pcDNA3 were maintained in RPMI 1640 supplemented with 
10% FBS, 2 niM L-glutamine, 100 units/mL penicillin G, and 100 pg/mL 
streptomycin. Al l cell lines were maintained at 37 in a humidified atmosphere 
with 5% CO2. 
3.1.2.2 Extraction of nine POPs from M. tenacissima 
The dried stems of M. tenacissima (20.3 kg) were extracted three times with 95% 
ethanol at room temperature for 3 days to yield a dark residue (3.4 kg) after 
evaporation. The residue (1.3 kg) was suspended in water (9 L) and then partitioned 
repeatedly with ethyl acetate (5 L x 3) to give ethyl acetate extract (460 g) and 
n-butanol extract (500 g). Apart of the ethyl acetate extract (270 g) was subjected to 
silica gel column chromatography (CC) and was eluted with petroleum ether 
(PE)/ethyl acetate (3:1 〜1:2), ethyl acetate, and then ethyl acetate/methanolmethanol 
(50:1, 10:1, 1:1), giving 18 fractions (Frs. A-R). POP62 (2.5 g) was recrystallized 
from fraction H. A white solid was deposited from fraction P, and the solid was then 
applied to preparative HPLC, yielding POP66 (8 mg), POP68 (36 mg) and POP69 
(51 mg). The residue of fraction P was subjected to MCI gel column chromatography 
(CC) (methanolmethanol/water 60%~100%) to give 5 sub-fractions (P-1 〜P-5). 
POP70 was obtained from fraction P-4 by preparative HPLC (methyl cyanide/water 
15% 〜54o/o, 15 ml/min, 0 〜192 min). fraction F was separated by MCI gel CC 
(methanol/water 50% 〜lOQo/o, then acetone) to afford 7 sub-fractions (fraction F-1 to 
fraction F-7). Fraction F-4 was subjected to silica gel CC (chloroform/methanol 
150:1) and then preparative HPLC (methyl cyanide/water 20% 〜50o/o, 15 ml/min, 0 
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〜192 min), giving POP56 (8 mg). Fraction F-5 was separated by silica gel CC 
(chloroform/methanol 100:1) and then purified by Sephadex LH-20 to yield POP53 
(30 mg). Similarly, fraction F-6 was subjected to CC (silica gel, chloroform/methanol 
150:1) and then preparative HPLC (methyl cyanide/water 20% 〜50。/。，15 ml/min, 0 
〜192 min), affording pure POP55 (14 mg). POP63 (1.2 g) was obtained from 
fraction I by MCI gel CC separation first (methanol/water 60%~100%) and then 
silica gel CC (chloroform/methanol 50:1). 
3.1.2.3 Sulforhodamine B (SRB) assay 
SRB assay was carried out to examine the cytotoxic enhancing effect of POPs 
towards the P-gp substrate anti-cancer drug doxorubicin in transfected cell line 
HEK293 MDRl and its transfection control cell line HEK293 pcDNA3 following the 
protocol described in Section 2.1.2.3. In addition, the 9 selected POPs were screened 
against sensitive human breast cancer cells MCF-7 for their cytotoxicity. Cells were 
seeded overnight in 96-well plates at a density of 4.0 x 10 cells per well in 100 |iL 
of culture medium and were then treated with various concentrations of POP (0-50 
|aM) for 72 h before detection of the cell viability. 
3.1.2.4 Flow cytometry assay 
p-gp overexpressing cell lines SW620/Ad300 and HEK293 MDRl and their 
respective control cell lines SW620 and HEK293 pcDNA3 were used. The 
intracellular retention of the fluorescence P-gp substrate rhodamine-123 was detected 
as the readout, whose fluorescence signal is proportional to its concentration. P-gp 
overexpressing cells have a high capacity to easily efflux rhodamine-123 and give a 
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relatively low fluorescence signal whereas non-P-gp overexpressing cells lend to 
retain rhodamine-123 and give a relatively high fluorescence signal. The P-gp 
inhibitory effect of the 9 POPs was investigated by comparing the rhodamine-123 
fluorescence signal with or without their presence. To detect the P-gp-mediated 
efflux, cells were trypsinized and incubated in 1 |ig/mL rhodamine-123 with or 
without 10 luM of POP in complete medium (phenol red-free RPMI 1640 with 10% 
FBS) at 37 in 5% CO2 for 30 min. Subsequently, the cells were washed twice with 
cold complete medium and then incubated for 1 h at 37 in phenol red-free 
medium continuing with or without 10 [ iM POP. Cells were then washed with cold 
PBS and placed on ice in the dark until flow cytometry analysis using BD 
LSRFortessa (BD Biosciences, MD, USA). PSC833 and verapamil, known P-gp 
inhibitors, were used as the positive controls. The activities of POPs in increasing the 
intracellular concentration of rhodamine-123 in resistant cancer cells SW620/Ad300 
and HEK293 MDRl were evaluated by comparing mean fluorescence signals in the 
absence or presence of POP and expressed as fluorescence index. The higher the 
fluorescence index, the stronger is the P-gp inhibitory effect. 
Fluorescence index 二 mean fluorescence signal with POP in resistant cells / mean 
fluorescence signal without POP in resistant cells 
3.1.2.5 P-gp ATPase assay 
The effect of POPs on recombinant human Pgp protein in a cell membrane fraction 
was detected using the Pgp-Glo™ Assay according to the manufacturer's instruction. 
ATP was first incubated with P-gp with or without 10 i iM of effective POP for 40 
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min at 37 and the reaction was stopped by adding the ATP Decteclion Reagent. 
Verapamil provided along with the kit was used at 500 j iM as the positive control 
and PSC833 and POP70 were also tested along with the 6 effective POPs. 
Luminescence signal was measured on a Wallace Victor〗1420 Multilabel counter 
(Perkin-Elmer, US). The luminescence signal is directly proportional to the ATP 
concentration in the reactions. The highest possible luminescence signal wi l l be 
obtained when no ATP is consumed; on the contrary, reactions where ATP has been 
consumed wi l l give raise to lower luminescent signals. Sodium orthovanadate is a 
selective inhibitor of P-gp and samples treated with sodium orthovanadate have no 
P-gp ATPase a c t i v i t y . i43 Sodium orthovanadate was used at 0.1 mM to block all 
ATPase activity and the difference in luminescence signal between sodium 
orthovanadate-treated samples and untreated samples gave the basal P-gp ATPase 
activity (ARLUbasai). Luminescence signal obtained with tested compounds (ARLUjc) 
can be compared to A R L U b a s a i give the ARLU ratio, ARLUic / ARLUb a s a i . 
If ARLUTC > ARLUbasai, the test compound is a stimulator of Pgp ATPase activity. 
I fARLUjc = ARLUbasai, the test compound has no effect on Pgp ATPase 
activity. 
I f ARLUTC < A R L U b a s a i , the test compound is an inhibitor of Pgp 
ATPase activity. 
The stimulation of ATPase activity is thought to be related with the interaction 
between P-gp and its substrate(s). In general, most compounds known to be 
transported by P-gp stimulate ATPase activity. 
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3.1.2.6 Immuno-blot/Western blot analysis 
Regulations of P-gp expression at the protein level by the 9 selected POPs were 
studied using Western blot analysis. The ineffective POP72 was used as the negative 
control. Resistant SW620/Ad300 cells were cultured in 60 mm diameter culture 
dishes at 5 x 10^  cell density. The medium was removed and substituted with fresh 
culture medium added with or without 10 [ iM of POP. After 24 h, cells were then 
washed with ice-cold PBS and lysed in 450 ^iL lysis buffer at 4°C for at least 15 min. 
The culture dishes were then scrapped and the suspensions were centrifudged at 
11,250 g for 10 min at 4 The supernatant was collected and reserved at -80 
until required. Protein concentration was quantified prior to analysis. Equal amounts 
of protein (15 |Lig) were resolved by 7.5% SDS-PAGE with a 5% stacking gel and 
transferred onto nitrocellulose membranes. The nitrocellulose blots were blocked in 
5% milk for 30 min at room temperature. The blots were then washed and incubated 
overnight with C219 monoclonal antibody at 1:1000 dilution. Following the washing, 
the blots were incubated with a secondary antibody anti-mouse IgG conjugated to 
horseradish peroxidase at 1:3000 dilution for 60 min at room temperature. The blots 
were washed and visualized with enhanced chemoluminescence detection and 
imaged by ChemiDoc XRS Molecular Imager system (Bio-rad, Hercules, CA, US). 
SW620 cells with low P-gp expression was used as negative control whereas the 
P-gp overexpressing MDRl transfected cells HEK293 MDRl was used as a positive 
control to confirm the P-gp band. The bands for (3-actin were also detected as internal 
reference using the p-actin monoclonal antibody at 1:1000 dilution and the secondary 
antibody anti-rabbit IgG conjugated to horseradish peroxidase at 1:2000 dilution. 
Band intensities were estimated by the Quantity One 1-D Analysis software and 
normalized using the following equation: 
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Normalized band density = (Band density of P-gp)/(Band density of (3-actin) 
3.1.2.7 Reverse transcription and quantitative real-time PGR 
Total RNA was isolated using the Trizol regent (Invitrogen, Carlsbad, CA). RNA (1 
jig) was reverse transcribed using the Transcriptor High Fidelity cDNA Synthesis Kit 
(Roche Applied Science, Indianapolis, IN). Quantitative real-time PGR was 
performed to measure the MDRl transcript expression using the KAPA SYBR FAST 
qPCR Kit (KapaBiosystems, Woburn, MA) in a LightCycler 480 Instrument I (Roche 
Applied Science). The human GAPDH RNA was amplified in parallel as the internal 
control for normalization. The specific primers used are as follows: 
MDRl (forward) 5‘-CCCATCATTGCAATAGCAGG-3 ‘ 
(reverse) 5 ‘ -GTTCAAACTTCTGCTCCTGA-3 ‘ ； and 
GAPDH (forward) 5'-AGCCACATCGCTCAGACAC-3' 
(reverse) 5, -GTTC AA ACTTCTGCTCCTGA-3 ’. 
PCRs were performed at 95°C for 5 min, followed by 50 cycles of 95®C for 10s and 
60°C for 10s. Fluorescence signal was acquired at the end of the elongation step of 
every PGR cycle (72°C for 1 Os) to monitor the increasing amount of amplified DNA. 
ACt was calculated by subtracting the Ct of GAPDH from that of MDRl transcript 
for each cell line. The human colon cancer cell line SW620 was used as the reference 
for comparison because the correlation between MDRl expression and drug 
resistance has been fully characterized in this cell line.i44 
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AACt was then calculated by subtracting the ACt of SW620 from the ACt of other 
cell lines. MDRl mRNA expression in individual cell line relative to SW620 cells 
was subsequently calculated by the equation 
3.1.2.8 Statistical analysis 
Data are expressed as mean value 士 S.E.M. unless otherwise specifically described 
from at least three independent experiments. The data were analyzed by one-way 
analysis of variance (ANOVA) followed by Dunnett's post hoc test, using GraphPad 
Prism 3.0. For the SRB cytotoxicity experiments, upaired t test was used to compare 
the IC50 values. The significance of differences was set at P < 0.05. 
3.2 Results 
3.2.1 Effects of nine selected POPs on the viability of sensitive human breast 
cancer MCF-7 cells 
The 9 selected POPs were initially screened against MCF-7 human breast cancer cell 
line, one of the three highly sensitive human cancer cell lines used in the Tumor 
Drug Screen at the National Cancer Institute (USA). None of the 9 selected POPs 
affected the cell proliferation of MCF-7 cells at concentration <50 |LIM after 72 h 
exposure as shown in Figure 3.1. 
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Figure 3.1 Cytotoxicity effect of 9 selected POPs on MCF-7 cells. (n=3) 
3.2.2 Effects of nine selected POPs on the viability of MDRl-transfected 
HEKl MDRl cell line and its control vector transfected cell line HEK293 
pcDNA3 
In addition to sensitive SW620 and drug-selected P-gp-overexpressing resistant 
SW620/Ad300 used in Chapter 2, another pair of transfected cell lines, MDRl 
transfected HEK293 MDRl and control vector transfected HEK293 pcDNA3, were 
used to examine the activities of the 9 selected POPs at 10 \iM on enhancing the 
cytotoxicity of doxorubicin. As shown in Table 3.1 and Figure 3.2, doxorubicin 
dose-dependently reduced cell viability and its IC50 value was 0.16 士 0.06 |aM in 
sensitive HEK293 pcDNA3 cells but developed significant resistance in the resistant 
HEK293 MDRl cells (0.82 士 0.03 [iM). Among the 9 POPs, the reversal effects of 
POP53, POP55, POP56, POP62, POP63 and POP66, were found to be higher than 
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50%, as expressed as the percentage reductions of the IC50 values of doxorubicin in 
resistant HEK293 MDRl cells while POP68, POP69 and POP70 were ineffective. 
This is in accordance with the results from SRB assay using SW620 and 
SW620/Ad300 cell lines described in Chapter 2. The IC50 values were summarized in 
Table 3.1. Al l the 9 selected POPs did not affect the cytotoxicity of doxorubicin in 
sensitive HEK293 pcDNA3 cells at 10 |LIM. In contrast, the effective POPs at 10 
were found to significantly enhance the cytotoxic effect of doxorubicin in the 
HEK293 MDRl cells. 
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Figure 3.2 MDR reversal effects of 9 POPs on sensitive HEK293 pcDNA3 and 
resistant HEK293 MDRl cells. (n=3) 
63 
Chapter 3. Mechanism of nine selected polyoxypregnane conipoiinds 
Table 3.1 Cytotoxicity of P-gp substrate anti-cancer drug doxorubicin and reversal of 
P-gp-mediated MDR by 6 effective POPs in HEK293 MDRl 
ICso ± SD (|iM) (% reduction) 
HEK293 pcDNA3 HEK293 MDRl 
Doxorubicin alone 0.16 士 0.06 rO.0%) 0.82 士 0.03 fO.0%) 
Effective POPs 
+ POP53(10 uM) 0.13 ±0.05 (18.8%) 0.35 ± 0.04 (57.3o/o) 
+ POP55 n o uM) 0.13 士 0.05 fl8.8%) 0.16 士 0.06 (80.5%) 
+ POP56 (10 uM) 0.15 士 0.06 (6.3%) 0.27 士 0.05 ( 6 7 . 1 % ) 
+ POP62 (10 uM) 0.14 士 0.05 (12.5%) 0.13 士 0.07 (84.1%) 
+ POP63(10 uM) 0.11 ±0.04(31.30/0) 0.05 ±0.14 (93.90/0) 
+ POP66 (10 uM) 0.16 士 0.07 (0.0%) 0.21 士 0.05 (74.4%) 
+ POP68 n o uM) 0.22 士 0.06 (-37.5%) 0.72 士 0.04 (12.2%) 
+ POP69 n o iiM) 0.19 士 0.03 (-18.8%) 0.65 士 0.04 (20.7%) 
+ POP70fl0 uM) 0.21 + 0.03 (-31.3%) 0.50 ± 0.05 (39.0%) 
3.2.3 Effects of nine selected POPs in inhibiting efflux of P-gp substrate 
To elucidate the underlying mechanism by which effective POPs sensitizes the MDR 
cells to chemotherapeutic drugs, the effect of these POPs on the accumulation of 
rhodamine-123 in P-gp overexpressing cell lines SW620/Ad300 and HEK293 
MDRl was further investigated. SW620 and HEK293 pcDNA served as negative 
control cell lines. As shown in Figure 3.2, SW620 and HEK293 pcDNA3 did not 
efflux the accumulated rhodamine-123 and resulted in high mean fluorescence 
signals 37951 士 811 and 25420 士 1567 respectively while P-gp-overexpressing 
SW629/Ad300 and HEK293 MDRl gave significantly lower intracellular 
concentration of rhodamine-123, 350 ± 122 and 2412 ± 355 respectively, and 
demonstrated the developed resistance. Known P-gp inhibitors PSC833 and 
verapamil were used as positive controls at 1 |LIM and 10 \iM concentration levels 
respectively. Consistent with literature reports,34，i45 they were found to significantly 
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reduce the efflux of rhodamine-123, giving raise to mean fluorescence signals 41993 
士 2794 and 1781 士 503 respectively in resistant SW620/Ad300 cells and 26932 士 
6498 and 7308 士 315130 respectively in resistant HEK293 MDRl cells. The 9 
selected POPs were tested at 50 [ iM for their effects in reducing the efflux of 
rhodamine-123 in resistant SW620/Ad300 and HEK293 MDRl cells and sensitive 
SW620 and HEK293 pcDNA3 cells and their mean fluorescence signals were 
summarized in Table 3.2 and Table 3.3. POP62 and POP68 were shown as 
representative data in Figure 3.3. Al l POPs showed no enhancement of accumulation 
of rhodamine-123 in sensitive SW620 and HEK293 pcDNA3 cells. The fluorescence 
index of POP53, POP55, POP56, POP62, POP63, POP66 were higher than 1.5-fold 
and were considered to be significantly increasing the intracellular concentration of 
rhodamine-123 in resistant SW620/Ad300 and HEK293 MDRl cells (Table 3.2 & 
Table 3.3). For other three ineffective POPs, their mean fluorescence signals and 
fluorescence index were also included in Table 3.2 and Table 3.3 and all fluorescence 
index were lower than 1.5-fold. 
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Figure 3.3 Representative data showing the effects of A) rhodamine-123 alone, B) 
rhodamine-123 with PSC833, C) rhodamine-123 with effective POP62 and D) 
rhodamine-123 with ineffective POP68 on the intracellular accumulation of P-gp 
substrate rhodamin-123 in sensitive SW620 and HEK293 pcDNA3 cell lines and 
resistant SW620/Ad300 and HEK293 MDRl cell lines. In all graphs, x-axis 
indicated the cell number whereas y-axis indicated the fluorescence signal. The 
histograms in black represent incubation with rhodamine-123 alone whereas the 
colored histograms represent the concomitant incubation of rhodamine-123 and the 
tested POPs. (n=3) 
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Table 3.2 Summary table of the mean fluorescence signal in SW620 and 
SW620/Ad300 
Cell lines (fluorescence index) 
SW620 SW620/Ad300 
Background 289 ±49 57 ± 2 
Rhol23 alone (50 |iM) 37951 ± 811 (1.0) 350 ± 122(1.0) 
Positive controls 
+ PSC833 (1 |iM) 41400 土 2225 (1.1) 41993 士 2794 (120.0) 
+ Verapamil (10 |iM) 36955 士 2484 (1.0) 1781 士 503 (5.1) 
Effective POPs 
+ POP53 (50 laM) 40892 士 1906 (1.1) 802 士 148 (2.3) 
+ POP55 (50 nM) 40122 士 2609 (1.1) 719 士 114 (2.1) 
+ POP56 (50 |LiM) 40248 士 2154 (1.1) 769 士 150 (2.2) 
+ POP62 (50 )iM) 43283 士 2967 (1.1) 1291 士 295 (3.7) 
+ POP63 (50 |iM) 40705 士 1469 (1.1) 2114 士 549 (6.0) 
+ POP66 (50 luiM) 40784 士 2403 (1.1) 618 ± 112 (1.8) 
Ineffective POPs 
+ POP68 (50 ixM) 39662 ±2151 (1.0) 394 ±31 (1.1) 
+ POP69 (50 [iM) 37758 士 2565 (1.0) 399 士 52 (1.1) 
+ POP70 (50 i iM) 37931 士 3133 (1.0) 449 ± 4 (1.3) 
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Table 3.3 Summary table of the mean fluorescence signal in HEK293 pcDNA3 and 
HEK293 MDRl 
Cell lines (fluorescence index) 
HEK293 pcDNA3 HEK293 MDRl 
Background 95 士 8.7 107 ±15 
Rhol23 alone (50 |aM) 25420 士 1567 (1.0) 2412 士 355 (1.0) 
Positive controls 
+ PSC833 (1 laM) 28106 士 1861 (1.1) 26932 士 6498 (11.2) 
+ Verapamil (10 [iM) 25961 士 1296 (1.0) 7308 ±3151 (3.0) 
Effective POPs 
+ POP53 (50 [iM) 25842 士 1517 (1.0) 4523 士 1660 (1.9) 
+ POP55 (50 |LIM) 26911 士 2339 (1.1) 4174 士 1320 (1.7) 
+ POP56 (50 i^M) 28891 士 1012 (1.1) 5636 士 2029 (2.3) 
+ POP62 (50 |iM) 27742 士 2045 (1.1) 6089 士 2471 (2.5) 
+ POP63 (50 |uM) 25109 士 1728 (1.0) 7230 士 2755 (3.0) 
+ POP66 (50 laM) 24466 士 986 (1.0) 3728 士 1355 (1.5) 
Ineffective POPs 
+ POP68 (50 |LIM) 23655 士 1023 (0.9) 2691 ±590 (1.1) 
+ POP69 (50 |iM) 25206 士 1704 (1.0) 2548 士 896 (1.1) 
+ POP70 (50 iLiM) 24613 士 2260 (1.0) 3314 ± 1093 (1.4) 
3.2.4 Effects of nine selected POPs in modulating P-gp ATPase activity 
The Pgp-Glo™ Assay Systems were used to test for the potential effect of the 
effective POP53, POP55, POP56, POP62, POP63 and POP66 on the P-gp ATPase 
activity. Verapamil provided along with the kit was used as positive control and 
DMSO was used as solvent control. Though PSC833 was a well-known P-gp 
inhibitor, it functionally inhibited P-gp-mediated efflux and down-regulated P-gp 
expression level but did not significantly alter basal ATPase activity.34，i46 PSC833 
and POP70 were used as negative controls. As summarized in Table 3.4, all 6 
effective POPs had ARLU ratio greater than 2.0, which is significantly difference to 
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the basal control value by one-way ANOVA, with POP53 having the highest value 
(3.9). The ARLU ratio represents the stimulatory effect of the ATPase activity. The 
higher the ARLU ratio, the stronger is the stimulation. The order of the ATPase 
activity stimulatory effect from highest to lowest can be arranged as POP53 > POP62 
> POP56 > POP55 > POP63 > POP66 while POP70 gave a ARLU ratio of 1.8 and 
was considered to have no effect on P-gp ATPase activity. As most P-gp substrates 
stimulate ATPase activity, those 6 effective POPs were considered to be P-gp 
substrates. 
Table 3.4 Summary table of the ARLU ratio of selected 6 effective POPs 
ARLU 士 SD ARLU ratio 
Basal 20469.5 ± 11885.2 1.0 ±0.0 
Verapamil (500 |iM) 106634.0 士 17875.9 5.2 士 0.6 
PSC833 (400 nM) 16567.5 士 21613.6 0.8 士 1.1 
POP53 (10 |iM) 80222.5 士 10798.4 3.9 士 0.2 
POP55 (10 fiM) 57862.5 士 16290.1 2.7 土 0.6 
POP56 (10 laM) 66912.5 士 17033.0 3.1 士 0.2 
POP62 (10 i^M) 76658.0 士 18690.9 3.7 士 0.3 
POP63 (10 |iM) 48673.0 士 12772.3 2.4 士 0.2 
POP66 (10 ^iM) 43547.5 士 11793.9 2.0 士 0.2 
POP70(1Q iiM) 38700.0 ±22181.8 1.8 ±0.4 
3.2.5 Effects of nine selected POPs in regulating P-gp protein expression 
POPs were tested for the possible modulation of P-gp protein expression to elicit 
their inhibitory effect towards P-gp-mediated efflux. Al l POPs were tested at 10 | iM 
in this assay as it is the highest effective concentration used in cytotoxicity assay. 
SW620/Ad300 cells were incubated with the 9 selected POPs for 24 h, followed by 
protein extraction for immuno-blot analysis for P-gp. As illustrated in Figure 3.3 and 
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Figure 3.4, all POPs tested did not significantly alter the P-gp expression after 24 h 
treatment. 
HEK293 SW62Q/Ad3QQ 
A) MDRl SW620 NT 53 62 68 72 
P-gp, 170 kDa mm mm mm mm _ 
/3 -actin, 45 kDa m m W m m m mmm mmm 
HEK293 SW62Q/Ad30Q 
B) MDRl SW620 NT 55 63 69 72 
P-gp, 170 kDa m m m i l l m m 
l^^^ H^PBif ^^^^^^^^ sdB^^^^^  
/5 -actin, 45 kDa mrnmm m m mtmam mmm mmm VMw 
HEK293 SW62Q/Ad3Q0 
C) MDRl SW620 NT 56 66 70 72 
P-gp, 170 kDa m m P « | M 灣 嘱 画 
3 -actin, 45 kDa —p~ mmm mmm mtrnm mmrnrn mmm^ mmmm 
Figure 3.4 P-gp protein expressions after 24 h treatment of 9 selected POPs, A) 
POP53, POP62 and POP68, B) POP55, POP63 and POP69 and C) POP56, POP66 
and POP70. (n二3) 
70 
Chapter 3. Median ism of nine selected polyoxypregnane coiiipoiiiids 
A) 
1.5-1 
m S:i:5S ^ ^ 
i :_JJJ_—. 
. / / / / / 
B) C) 
1.5-1 1.5-1 
0 ~r ^ —r-11•�-_ • w 4 i i i.�-p^ i 4 4I I 1 i i i i i i i i i i i i i / / / / / / / z 
令。 令。 
Figure 3.5 Effects of 9 selected POPs, A) POP53, POP62 and POP68, B) POP55, 
POP63 and POP69 and C) POP56, POP66 and POP70 on regulating P-gp protein 
expression after 24 h treatment. The ratio of P-gp expression in SW620/Ad300 
divided by that in HEK293 MDRl was calculated after normalization to P-actin. 
(n=3) 
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3.2.6 MDRl mRNA expression in various cell lines 
MDRl mRNA expressions in different cell lines used in this study were detected by 
qPCR. SW620, known to be expressing low MDRl mRNA, was used as internal 
reference. Drug-selected P-gp overexpressing SW620/Ad300 and MDRl gene 
transfected P-gp overexpressing HEK293 MDRl cells had remarkably higher MDRl 
expressions than other cells whereas colon carcinoma Caco-2 cells and transfection 
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Figure 3.6 Relative MDRl mRNA expressions in different cell lines. (n=3) 
3.3 Discussion 
Only two POPs (POP55 & POP66) isolated from M. tenacissima have only been 
reported previously to inhibit P-gp-mediated efflux. Several novel POPs have 
been discovered from M. tenacissima by our research team. The present study is the 
first to show the P-gp-, MRPl- and ABCG2-mediated MDR reversal effect of 
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various POPs found in the extract of M tenacissima. In Chapter 2, 30 POPs have 
been tested for their MDR reversal effect and nine POPs have been selected for more 
in-depth mechanistic study according to their chemical structures and potential 
biotransformation. The aim of the study described in this chapter is to explore the 
underlying mechanism of the six effective POPs (POP53, POP55, POP56, POP62, 
POP63 and POP66) in modulating P-gp-mediated MDR. In parallel, the three 
ineffective but most abundant POPs in M. tenacissima (POP68, POP69 and POP70) 
were also studied as negative controls. 
3.3.1 Effective POPs are targeting specifically P-gp overexpression 
The results of this study showed that all nine selected POPs did not reduce the 
viability of sensitive human breast cancer cells MCF-7, which is one of the three 
highly sensitive human cancer cell lines used in the Tumor Drug Screen at the 
National Cancer Institute (USA) (Figures 3.1-3.2). Since all nine POPs were found to 
be non-cytotoxic towards both cell lines even at 50 [ iM concentration level, they 
were evaluated for potential MDR reversal at 0.4, 2, or 10 .uM when combined with 
other anticancer drugs. 
In previous chapter, the six effective POPs were screened in SRB assay using human 
colon carcinoma SW620 cell line and its doxombicin-selected P-gp overexpressing 
subline SW620/Ad300. The six effective POPs were found to significantly reduce the 
IC50 values of doxorubicin, a known P-gp substrate anti-cancer drug in 
SW620/Ad300 but not SW620 (Table 2.1). Since the resistance phenotype in 
SW620/Ad300 may involve factors other than the overexpression of P-gp, it raises 
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doubt as to whether the circumvention of resistance in this cell line model is solely 
due to the inhibition of P-gp. Therefore, the six POPs were tested again using another 
more well-defined cell line model (i.e. HEK293 MDRl) where the P-gp 
overexpression is mediated by stable transfection. The corresponding transfection 
control HEK293 pcDNA3 cell line was used as the negative control for comparison. 
Importantly and agreeing with the data presented in Chapter 2, the six POPs were 
found to enhance the cytotoxicity of doxorubicin only in the MDRl -transfected cells, 
HEK293 MDRl , but not non-P-gp overexpressing cells, HEK293 pcDNA3 (Table 
3.1). This result suggested that the six effective POPs were specifically targeting 
P-gp overexpressing cells. While the other three ineffective POPs, POP68, POP69 
and POP70 showed no enhancement in the cytotoxicity in HEK293 MDRl as well as 
SW620/Ad300 (Tables 2.2, 3.1), and thus were considered to be ineffective in 
modulating P-gp-mediated MDR. 
3.3.2 Mechanistic understanding the circumvention of MDR by the effective 
POPs 
Given that MDR remains a major obstacle in cancer chemotherapy, the 
understanding of mechanisms contributing to MDR and the search for effective 
means for their circumvention have attracted so much attention in recent decades. To 
this end, TCM has been reported to be useful in reversing MDR. The effective 
constituents range from crude extract, pure compounds isolated from the herbs, to 
TCM formulation. Interestingly, most studies have focused on the circumvention of 
P-gp-mediated MDR, probably due to the fact that P-gp is the most extensively 
studied MDR transporter. However, they are always lacking in a clear mechanistic 
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understanding for the apparent MDR reversal. In our study, we attempted to 
elucidate the underlying mechanisms of reversal of P-gp-mediated MDR by the six 
effective POPs. 
3.3.2.1 Relative potency for the reversal of P-gp-mediated MDR 
To study the underlying mechanism, it is better to understand the potency of the six 
effective POPs first. Since the six POPs were significantly more effective at 10 pM 
than 2 ‘uM, the six POPs were tested at 10 pM in HEK293 pair of cell lines. The 
effective POPs at lower concentration levels were also tested and their potency rank 
order according to their % reduction and effective concentration were obtained and 
described in Section 2.2.1, which is different from just considering the % reduction 
of POPs at 10 ‘uM. From the SRB assay result obtained from the SW620 pair of cell 
lines, the potency rank order of the six effective POPs at 10 ‘uM is POP62 = 
POP63 > POP55 = POP56 > POP66 > POP53 (Table 2.1), whereas in the HEK293 
pair of cell lines, the potency rank order is POP63 > POP62 = POP55 > POP66 > 
POP56 > POP53 (Table 3.1). The slight difference in the rank order in the two cell 
line models may be due to the different P-gp expression level in the SW620/Ad300 
and HEK293 MDRl cells. In overall, POP63 is the most potent POPs among the six 
effective POPs, followed by POP62 and then POP55, while the potencies of POP56 
and POP66 are similar but less than POP55, the least potent POP among the six 
effective POPs is POP53, i.e. POP63 > POP62 > POP55 > POP66 = POP56 > 
POP53. 
3.3.2.2 Inhibition of P-gp-mediated drug efflux across cell membrane by the 
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effective POPs 
Results from flow cytometry analysis illustrated that the six effective POPs 
significantly increased the intracellular concentration of rhodamine-123, a known 
P-gp substrate, in P-gp overexpressing cell lines SW620/Ad300 and HEK293 MDRl 
but not in non-P-gp overexpressing cell lines SW620 and HEK293 pcDNA3 (Tables 
3.2-3.3). The results suggested that the six POPs circumvent P-gp-mediated MDR by 
inhibiting the efflux of P-gp substrate anti-cancer therapeutics such as doxorubicin. 
The results are in accordance with that obtained from SRB assay and once again, 
showed that the six effective POPs are specifically targeting cells that overexpress 
P-gp. 
3.3.2.3 Stimulation of ATPase by the effective POPs 
ABC drug transporters, including P-gp, are normally expressed as polypeptides 
organized in four domains, two transmembrane domains (TMDs) and two 
cytoplasmic nucleotide binding domains (NBDs)."^^ Although P-gp is well known to 
utilize energy generated from ATP hydrolysis to mediate drug efflux, the precise 
mechanism is still not c l e a r . N e v e r t h e l e s s , modulating the ATP binding sites of 
P-gp such as binding phosphate analogue sodium orthovanadate can inhibit the efflux 
transportation of P-gpi49，i50 By using the Pgp-Glo™ ATPase Assay, we are able to 
determine whether the POPs inhibit or stimulate ATPase activity and subsequently 
categorize them into P-gp inhibitor or P-gp substrate respectively. The result showed 
that all six effective POPs were P-gp substrates while the ineffective POP70 was not 
a P-gp substrate (Table 3.4). 
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Verapamil is widely considered to be a P-gp inhibitor and a P-gp substrate while 
sodium orthovanadate is regarded as a P-gp inhibitor only.'^'''^^ The differentiation is 
derived from their mechanisms of interaction with P-gp. Sodium orthovanadate binds 
to ATP binding sites of P-gp and interrupt the conformation change of P-gp, hence it 
acts as a noncompetitive P-gp inhibitor. Verapamil, on the other hand, is a P-gp 
substrate and competitively inhibits the transportation of P-gp. Similarly, as P-gp 
substrates, the six effective POPs may also compete for the P-gp substrate binding 
sites and hence increase the intracellular concentration of other P-gp substrates, such 
as rhodamine-123 and doxorubicin. Further studies are warranted to confirm this 
mechanism. 
3.3.2.4 No effect of POPs on the alteration of P-gp expression 
Numerous natural compounds have been reported to decrease the P-gp expression 
level in resistant cancer cells to circumvent P-gp-mediated mdr/06,115,118,153,154 
Furthermore, the effect of the six effective POPs on the levels of P-gp in 
SW620/Ad300 was determined. After 24 h incubation of POP, the P-gp expression 
level in SW620/Ad300 was not significantly changed as shown in Figure 3.3 and 
Figure 3.4. Therefore, the MDR reversal effect of the six effective POPs is unlikely 
to be due to the down-regulation of P-gp in the resistant cells. P-gp cell surface 
expression confers the efflux of anti-cancer drugs out of the cells but cytoplasmic 
P-gp does not. Although the total protein expression of P-gp did not change 
significantly, there is a possibility that the location of P-gp changed from cell surface 
to cytoplasm and results in decrease in efflux and thereby circumventing MDR. * 55 
Fluorescence staining of cell surface P-gp can be further carried out to verify this. 
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Since P-gp is widely expressed in many normal tissues, such as gastrointestinal tract, 
this property of the POPs is beneficial because potential adverse effect and drug-drug 
interaction due to reduced P-gp level at the drug absorption site wil l be less likely to 
occur. Moreover, since the six POPs were P-gp substrates and effective in inhibiting 
P-gp efflux, they might be more effective in inhibition at sites where P-gp expression 
level is high. Since MDR is often caused by P-gp overexpression, the specific 
targeting of P-gp by the effective POPs could result in a preferential accumulation of 
the P-gp substrate anticancer drugs in the resistant cancer cells and therefore 
enhancing the anticancer effect. On the other hand, the normal cells with relatively 
low P-gp expression wil l be spared from the cytotoxic effect, even upon exposure to 
the POPs. 
3.3.2.5 An overall summary of the mechanism of MDR reversal by the effective 
POPs 
In summary, a proposed mechanism of action of the six effective POPs is shown in 
Figure 3.6. In resistant cancer cells overexpressing P-gp, the cells can survive even 
with increased dose of anti-cancer chemotherapeutics by actively transporting the 
chemotherapeutics out of the cells. Since P-gp can transport drugs that are 
structurally unrelated, P-gp overexpressing cancer cells are resistant to a broad 
spectrum of anti-cancer chemotherapeutics. When exposed to POP53, POP55, 
POP56, POP62, POP63 or POP66 at effective concentration, the intracellular 
concentration of P-gp substrate chemotherapeutics were significantly increased, 
resulting in notably enhanced cytotoxic effect in cancer cells, mainly due to the 
intervention of the effective POPs with ATPase leading to the inhibition of 
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P-gp-mediated efflux without alteration of the P-gp expression. 
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Figure 3.7 Proposed mechanism of action of the six effective POPs (POP53, POP55, 
POP56, POP62, POP63 and POP66) in circumventing P-gp-mediated MDR. 
3.3.3 Implication in drug disposition and drug-drug interactions 
P-gp is also known to be a major determinant in drug disposition in humans. The oral 
bioavailability of P-gp substrate drugs such as fexofenadine significantly increased 
when P-gp inhibitor such as erythromycin or ketoconazole was co-administered. ^  ^  ^  
P-gp distributes in many parts of our bodies and is concentrated in intestine and 
brain.45，46 p.gp serves as a permeability barrier in blood-brain barrier and the 
absorption sites such as intestinal epithelial. Therefore, it should be careful when 
P-gp inhibitors are used together with other therapeutic drugs. Lethal drug-drug 
interaction between high dose of quercetin, which is widely distributed flavonoids in 
natural products and is a P-gp inhibitor, and digoxin, a cardiovascular drug, has been 
reported. 109 Since POPs are more selective to P-gp overexpressing cells specifically 
and may not targeting other sites, it may be safe to co-administer the POPs with other 
chemotherapeutics, especially anti-cancer drugs to circumvent MDR. The six 
effective POPs may be safe after administration to cancer patients. However, the 
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safety in using POPs in chemotherapy requires further study. The in vivo toxicity 
towards various organs of the three abundant POP68, POP69 and POP70 are 
discussed in Chapter 4. 
3.3.4 Additional information for the structure activity relationship (SAR) 
In addition, since POP70 was found to be a non-P-gp substrate, once again, the sugar 
moiety at R position of POPs should not exceed two pyranoses in order to be 
transported by P-gp. From the P-gp ATPase results, POP53 and POP62 had the 
highest ARLU ratios among the six effective POPs. Taking their structures into 
account, a methyl isobutyl at Ri position favors their interaction with P-gp. 
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CHAPTER 4. EFFECTS OF CRUDE EXTRACT AND THREE 
MAJOR POLYOXYPREGNANES (POPS) OF MARSDENIA 
TENACISSIMA 
TCM herbs have been used in the form of decoction (the herbal extract) for 
thousands of years. Besides investigating the active compounds individually, it is 
worthwhile to study the herbal extract form of M tenacissima as well. POP68, 
POP69 and POP70 contribute approximately 53.6% in M. tenacissima extract. 
According to data presented in Chapter 2, these three major POPs themselves did not 
circumvent any of the P-gp-, MRP1-, or ABCG2-mediated MDR. Moreover, as 
described in Chapter 3, the three major POPs were found to have no inhibitory effect 
on P-gp efflux in either cellular transportation or transepithelial transportation. 
Moreover, POP70 did not have any notable effect on P-gp ATPase activity, indicating 
that POP70 is not a P-gp substrate or a P-gp inhibitor. In addition, the three major 
POPs did not regulate P-gp expression. A l l these findings seem to point to the fact 
that POP68, POP69 and POP70, even though contributing more than half of the 
extract of M tenacissima, are not involved in the apparent circumvention of MDR. 
Nonetheless, as aforementioned, these three abundant POPs (POP68, POP69 and 
POP70) might be possibly converted to effective POPs (POP68-POP62-POP53; 
POP69-POP63-POP55; POP70-POP66-POP56) in vivo via metabolic 
biotransformation. The converted POPs were effective in circumventing 
P-gp-mediated MDR and POP53, POP55 and POP63 were also effective in 
modulating MRPl-mediated MDR. In this study, such metabolic biotransformation 
of these three ineffective POPs (POP68, POP69 and POP70) were investigated and 
123 125 127 
their safety was also eva luated.， ‘ 
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4.1 Materials and Methods 
4.1.1 Chemicals, Materials and Reagents 
Biotransformation Assay 
Chemical/Reagent/Equipment Product Brand Catalog Number 
BBL brain heart infusion (BHI) medium BD Biosciences 221813 




4.1.2.1 Preparation of M tenacissima extract, artificial mixture and three fractions 
The dried stems of M tenacissima (20.3 kg) were extracted three times with 95% 
ethanol at room temperature for 3 days, affording a dark residue (3.4 kg) after 
evaporation. The residue (1.3 kg) was suspended in water (9 L) and then partitioned 
repeatedly with ethyl acetate (5 L x 3) to give ethyl acetate extract (460 g) and 
n-butanol (500 g). The ethyl acetate extract, containing effective and ineffective 
POPs, was defined to be the crude extract used in the study (Figure 4.1, Table 4.1). 
Artificial mixture of POP68, POP69 and POP70 were prepared according to their 
compositions in the crude extract. 
Three fractions (Figure 4.2) were prepared by silica gel CC separation. Fraction 1 
does not contain POPs and serves as a control fraction with all the remaining 
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components eluted from the column after removing fraction 2 and fraction 3. 
Fraction 2 contains POP68, POP69 and POP70 and their content and ratio were 
measured and are listed in Table 4.1. Fraction 3 contains POPs other than POP68, 
POP69 and POP70. The HPLC chromatograms of the three fractions are shown in 
Figure 4.1. 
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Figure 4.1 HPLC chromatograms of crude extract (ethyl acetate extract) with the 
indications of A) ineffective POPs and B) effective POPs. 
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Table 4.1 Ratio and content of POP68, POP69 and POP70 in extract and fraction 2 
Content Content Content Total Ratio of POP68: 
of POP68 of POP69 of POP70 content of POP69: POP70 
(%) (%) (%) three 
POPs (%) 
Crude extract 21.2 15.2 17.2 53.6 1.4:1:1.1 
Fraction 2 24.1 16.2 24.9 65.2 1.5:1:1.5 
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Figure 4.2 HPLC chromatograms of A) fraction 1，B) fraction 2 and C) fraction 3. 
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4.1.2.2 Sulforhodamine B assay 
SRB assay was carried out to evaluate the relative effectiveness of crude extract of M 
tenacissima, the artificial mixture of POP68, POP69 and POP70, and the three 
fractions of M. tenacissima in enhancing the cytotoxicity of the P-gp substrate 
anti-cancer drug doxorubicin in SW620 and its P-gp overexpressing resistant subline 
SW620/Ad300 following the protocol described above in Section 2.1.2.3. 
4.1.2.3 Biotransformation study of POP68, POP69 and POP70 
Hydrolysis is one of the major metabolic pathways occuring along gastrointestinal 
t r a c t . 156 We made use of the microbiota extracted from human fecal samples to 
investigate our hypothesized potential biotransformation of ineffective POP68, 
POP69 and POP70 to respective effective POPs in modulating P-gp activity. Fresh 
human fecal samples were collected form 4 healthy Chinese volunteers (two male 
and two female, 20-32 years) according to a p r o t o c o l”？ Four fecal samples (5 g each) 
were pooled together and mixed well with 30 mL culture medium, which was 
prepared by adding 0.05 mg of vitamin K l , 0.5 mg of human bovine and 50 mg of 
L-cystine in 100 mL BHI medium (0.37 mg/mL). The resulting fecal suspension was 
centrifuged at 200 g for 5 min and supernatant decanted and centrifuged at 5,000 g 
for 30 min. Then the precipitate was re-suspended with 10 mL BHI medium to 
generate the intestinal microbiota solution used in our study. The biotransformation 
of the three ineffective POPs by human intestinal bacteria was conducted in a 0.5 mL 
incubation system containing 25 \xL intestinal microbiota solution and 2.5 jiL stock 
solution in DMSO in BHI medium. The incubation system was anaerobically 
incubated with 50 pM POP68, 50‘uM POP69, 50 ‘uM POP70, 50 ‘ug/mL crude extract 
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or 50 ,Lig/mL artificial mixture at 37 ^C in a GasPakTM EZ Anaerobe Pouch System 
for 0 h, 4 h, 9 h, 12 h, 24 h, 36 h and 48 h. Reactions were stopped by addition of 0.5 
niL ice-cold methanol, followed by immediate centrifugation at 15,000 g for 10 min. 
1 niL aliquot of supernatant was collected for analysis. POPs were analyzed by 
HPLC-MS. 
Metabolite formation (%) was the concentration (pM) of metabolite at sampling time 
(t) divided by the initial concentration (‘uM) of parental POPs times 100%, Metabolic 
rate was the difference between the initial concentration and the concentration at 
sampling time divided by the initial concentration of POP times 100%, 
Metabolite formation (%) = C t (metabolite，m)丨 C o (parental compound, m M ) X 1 0 0 % 
Metabolic rate (%) = (Co(pop, Ct (POP, MM))丨 Co(pop，MM) X 100% 
4.1.2.4 HPLC-MS analysis 
The HPLC analysis was performed on a symmetry C18 5 |im column (4.6 x 150mm, 
Agilent Techonologies, U.S.) and a symmetry C18 5 [im guard column (4.6 x 5mm, 
Agilent Techonologies, U.S.). The mobile phases consisted of methanol (A) and 2 
mM ammonium acetate (B). For the analysis of POP68, POP69 and POP70, the 
mobile phase of A:B was 70%:30% with the flow rate 0.70 mL/min. For the analysis 
of POP62, POP63 and POP66, the mobile phase of A:B was 75%:25% with the flow 
rate 0.75 mL/min. While for the analysis of POP53, POP55 and POP56, the mobile 
phase of A:B was 80%:20% with the flow rate 0.80 mL/min. The ESI source was 
operated in positive ionization mode. The conditions of MS analysis were as follows: 
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ionspray voltage, 5500 V; curtain gas, 20 psi; Gas 1, 40 psi; Gas 2, 20 psi; source 
temperature, 400°C. Al l gases used were nitrogen. Declustering potential and 
entrance potential were set at 80 V and 10 V, respectively. Quantification was 
performed using multiple reaction monitoring (MUM). The MRM transitions and the 
collision energy used for the nine POPs and the internal standard ginsenoside Rbl 
are shown in Table 4.2. 
Table 4.2 The MRM transitions and the collision energy used for nine POPs and the 
internal standard ginsenoside Rbl 
Compound MRM transitions (m/z) Collision Energy (eV) 
POP53 491—347; 513—329 15; 40 
POP55 533—329; 533—203 40; 50 
POP56 489—347; 489—329 20; 10 
POP62 817—757; 817—83 60; 103 
POP63 837->715; 837-^777 50; 50 
POP66 815^85; 815->755 80; 60 
POP68 979—919; 977—817 70; 47 
POP69 999—939; 977—817 24; 42 
POP70 977—917; 977—817 36; 45 
Ginsenoside Rbl 1131—365 m 
4.1.2.5 Animal care and housing conditions 
Male BALB/c mice from age 6 to 8 weeks were provided by Laboratory Animal 
Services Center of The Chinese University of Hong Kong. Animals were divided into 
two groups with four mice in each group. Al l animals were maintained in a 
pathogen-free environment air-conditioned at 24 士 2°C with a standard 12 h light/12 
h dark cycle. Animals were allowed access to tap water and standard pellet diet ad 
libitum. Care of animals and all experimental procedures were approved by the 
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Animal Ethics Committee of The Chinese University of Hong Kong. 
4.1.2.6 Toxicity studies of fraction 2 in mice 
Mice were randomly divided into two groups (n=3) for oral or intravenous 
administration of fraction 2. Fraction 2 was dissolved in 5% Tween-80 in water or 
5% Tween-80 in normal saline for oral (p.o.) and intravenous (i.v.) administration at 
the dose of 200 mg/kg and 20 mg/kg, respectively. Control mice were administered 
with equal volumes of distilled water or saline. The general health of the mice was 
monitored throughout the study. After sacrifice at 24 h post-administration, the brain, 
heart, lung, stomach, small intestine, colon, kidney and liver were removed from 
each mouse, rinsed with saline and weighed. The organs were then immediately 
immersed in 4% paraformaldehyde for tissue fixation. The tissue samples were 
incubated in 4% paraformaldehyde for 2 h with shaking on an orbital shaker at 150 
rpm. Then, the tissue samples were rinsed with distilled water and incubated 
overnight in 30% sucrose solution with shaking on an orbital shaker at 150 rpm for 
cryopreservation. Tissue embedding proceeded when tissue samples sunk to the 
bottom of the tubes in an upright position. Tissue samples wil l be embedded in OCT 
reagent and immersed in 2-methylbutane cooled with liquid nitrogen. The frozen 
sections wil l be stored at -80°C until sectioning with cryotome. Tissue samples wil l 
be sectioned at 5 \xm and incubated at room temperature for 20-30 mins for 
adherence to slides and then subjected to hematoxylin and eosin staining. Histology 
of sections were viewed and photographed with a brightfield microscope with 1 OOx 
magnification. 
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4.1.2.7 Statistical analysis 
Data are expressed as mean value 士 S.E.M. unless otherwise specified from at least 
three independent experiments. The data were analyzed by one-way analysis of 
variance (ANOVA) followed by Dunnett's post hoc test, using GraphPad Prism 3.0. 
For the SRB cytotoxicity experiments, upaired t test was used to compare the IC50 
values. The significance of differences was set at 尸 < 0.05. 
4.2 Results 
4.2.1 Effects of crude extract, artificial mixture on the viability of sensitive 
human breast cancer MCF-7 cells 
As mentioned in previous chapter, MCF-7 human breast cancer cell line is one of the 
three highly sensitive human cancer cell lines used in the Tumor Drug Screen at the 
National Cancer Institute (USA). Therefore, we tested the crude extract, artificial 
mixture and the three fractions (0-50 jjg/mL) in MCF-7 cells. As shown in Figure 4.5, 
artificial mixture and fraction 1 were not cytotoxic towards MCF-7. However, slight 
cytotoxicity was observed after treating MCF-7 with crude extract, fraction 2 and 
fraction 3 at 25.5 ‘ug/mL and 50 pg/mL concentration levels. Among the three 
treatments, the cytotoxicity of fraction 2 was the highest, followed by fraction 3 and 
then crude extract at 50 ‘ug/mL. 
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Figure 4.3 Cytotoxicity of A) crude extract, B) artificial mixture, C) fraction 1, D) 
fraction 2 and E) fraction 3 on MCF-7 cells. (n=3) 
4.2.2 Effects of crude extract, artificial mixture on the viability of sensitive 
SW620 and P-gp-overexpressing resistant SW620/Ad300 cells 
To assess the ability to circumvent P-gp-mediated MDR, sensitive SW620 and 
P-gp-overexpressing resistant SW620/Ad300 were used to examine the activities of 
crude extract, artificial mixture and the three fractions separately on lowering the 
IC50 of doxorubicin. Doxorubicin dose-dependently reduced cell viability and its IC50 
values was 0.09 士 0.05 \xM in sensitive SW620 cells and 8.10 士 0.03 | iM in resistant 
SW620/Ad300 cells. Since all the treatment groups showed no cytotoxicity at 12.5 
pg/mL in previous study (Figure 4.5), 10 ‘ug/mL were chosen in studying their effects 
in enhancing the cytotoxicity of doxorubicin in resistant SW620/Ad300 cells and 
sensitive SW620 cells, and the IC50 values are summarized in Table 4.3. Al l 
treatment groups showed no enhancement of cytotoxicity of doxorubicin in sensitive 
SW620 cells. The % reductions of crude extract and fraction 3 were higher than 50% 
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and were considered to be effective in lowering the IC5() value of doxorubicin in 
resistant SW620/Ad300 cells (Table 4.3). Artificial mixture, fraction 1 and fraction 2, 
containing POP68, POP69 and POP70, had a reduction lower than 50% and were 
considered ineffective. 
Table 4.3 Cytotoxicity of P-gp substrate anti-cancer drug doxorubicin and reversal of 
P-gp-mediated MDR by crude extract, artificial mixture and fractions 
IC50 士 SD (|iM) (0/0 reduction) 
SW620 SW62Q/Ad3Q0 
Treatments 
+ crude extract (10 ug/mL) 0.04 ±0.11 (20.0%) 11.49 士 0.07 (84.9%)* 
+ artificial mixture (lOug/mL) 0.06 士 0.13 (-20.0%) 6.81 士 0.04 (3.5%) 
+ fraction 1 (10 ug/mL) 0.09 士 0.07 (0.0%) 5.76 士 0.04 (28.9%) 
+ fraction 2 (10 ug/mL) 0.10 士 0.05 (-11.0%) 7.18 士 0.04 (11.4%) 
+ fraction 3(10 ug/mL) 0.10 士 0.08 M 1.0%) 1.08 士 0.07 (86.7%)___ 
* % reduction was calculated by comparing the IC5 0 values to that of the doxorubicin 
alone treatment group (internal reference) within each set of experiment. 
4.2.3 Metabolites of POP68, POP69 and POP70 after incubation with human 
intestinal microbiota 
The potential biotransformation of the three major POPs POP68, POP69 and POP70 
was studied by incubating POP68, POP69 or POP70 individually, artificial mixture 
or crude extract in the intestinal microbiota extracted from human feces. Since 
POP68, POP69 and POP70 were proposed to be metabolized to form POP53 and/or 
POP62, POP55 and/or POP63, POP56 and/or POP66 respectively as mentioned 
under Section 2.3.2 in Chapter 2, both the metabolized POPs and the original parent 
POPs were detected by HPLC-MS as described. As shown in Figure 4.3, POP62 (but 
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not POP53) was detected from the pure POP68-incubation. POP63 and POP66 were 
also detected in pure POP69- and POP70-incubations respectively but POP55 or 
POP56 were not detected in the corresponding cases. For individual POP treatments, 
POP66 had the highest metabolite formation percentage, reaching 20% at 48 h, 
followed by POP62, more than 10% after 9 h and was maintained until 48 h, and 
then by POP63, reaching 8% at 48 h. Among POP68, POP69 and POP70, POP70 
was found to be metabolized most, followed by POP68 and then POP69. On the 
other hand, POP62, POP63 and POP66 were found to have different metabolite 
formation percentage in the treatment of artificial mixture, 8% of POP66 and POP62 
were detected at 48 h whereas 6% of POP63 was detected at 48 h. On the other hand, 
POP62 and POP66 were found to have significantly lower concentrations in the 
treatment of artificial mixture when compared that in pure POP68- and 
POP70-incubations, respectively. 
In the crude extract treatment group, POP68, POP69 and POP70 were all completely 
metabolized after 4 h incubation, while their metabolic transformation rates 
determined at 4 h were about 20%, 40% and 30% correspondingly (Figure 4.4). 
Therefore, more time points before 4 h should be assessed and are currently under 
progress. POP68 had the lowest metabolic rate but its metabolite POP62 had the 
highest concentration among the metabolites formed, while POP63 and POP66 had 
similar metabolite formation percentage %, around 10% after 9 h, in the crude extract 
treatment group (Figure 4.3). 
92 
Chapter 4. tZtTecl o f crude extract and three major polyoxypregnane conipoi inds 
Metabolite formation (%) of pure POPs 
i POP62 
I 20- — POP63 
•2 i r POP66 ” - /e r r : 
I ^ 
0 1 1 1 
0 20 40 60 
Timepoint (h) 
Metabolite formation (%) of artificial mixture Metabolite formation (%) of crude extract 
-10"! POP62 7 40l + POP62 
- g . « POP63 t J + POP63 
.2 + POP66 a A + POP66 
f r 
爱 0-1 1 1 1 o4 1 1 ‘ 
0 20 40 60 0 20 40 60 
Timepoint (h) Timepoint (h) 
Figure 4.4 Metabolite formations of POP62, POP63 and POP66 after incubating A) 
POP68, POP69 or POP70 individually, B) artificial mixture and C) crude extract in 
the human intestinal microbiota solution. (n=3) 
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Figure 4.5 Metabolic rates of POP68, POP69 and POP70 after incubating the crude 
extract in human intestinal microbiota solution. (n=3) 
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4.2.4 Toxicity of fraction 2 in mice 
From the in vitro studies, fraction 2 was found to be toxic to the sensitive human 
breast cancer MCF-7 cells at concentrations higher than 10 |ig/mL (Figure 4.5). 
Since fraction 2 contains the three major POPs POP68, POP69 and POP70, which 
could be converted into effective POPs POP62, POP63 and POP66, respectively, 
their potential toxicity towards different body organs were examined in vivo. The 
possible toxic effects were studied by treating mice with 5% Tween-80 in saline as 
the vehicle control and 200 mg/kg (p.o.) and 20 mg/kg (i.v.) of fraction 2 and 
analyzing the histopathology of different organs after sacrifice at 24 h after 
administration. 
After the mice were sacrificed, the brain, heart, lung, stomach, small intestine, colon, 
kidney and liver were fixed for hematoxylin and eosin staining for histopathological 
observation. There was no significant difference between the weights of most organs 
and the physical appearance of the organs (such as color or size) between the vehicle 
and fraction 2 treatment groups (Figure 4.6). Organ sections stained with 
hematoxylin and eosin indicated that fraction 2 did not induce cell swelling, necrotic 
damage or hemorrhage in various organs (Figure 4.7). Apparently, fraction 2 did not 
induce toxicity to various body organs treated with oral dose of 200 mg/kg or 
intravenous dose of 20 mg/kg up to 24 h, as verified by histopathological 
examination. 
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Figure 4.6 Weight of various organs sacrifice in male BALB/c mice after A) oral 
administration (200 mg/kg) and B) intravenously administration (20 mg/kg) of 
fraction 2 for 24 h. (n=3) 
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administration of fraction 2 (200 mg/kg) or B) intravenous injection of fraction 2 (20 
mg/kg) for 24 h. The scale bar indicated by the black bold line refers to 50 pm. The 
images are representative of results from three mice for each group. (n=3) 
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4.3 Discussion 
Hydrolysis represents an important drug metabolic reaction mediated by enzymes 
such as glycoside hydrolases, which can be found in intestine to convert glycosides 
to aglycones.140 As proposed in Chapter 2, when crude extract or a mixture 
containing POP68, POP69 and/or POP70 is administered orally, our hypothesis is 
that ineffective POP68, POP69 and POP70 could be converted into effective POPs, 
POP53 or POP62, POP55 or POP63 and POP56 or POP66 in vivo respectively, 
leading to circumvent MDR. The evidence for this biotransformation was revealed in 
the present study. 
In Chapter 2, we investigated the apparent circumvention of P-gp-mediated MDR by 
30 POPs in M. tenacissima crude extract, where 11 POPs were found to be effective. 
However, these 11 POPs compose only a small proportion in the crude extract, as 
shown in Figure 4.1 while the crude extract itself was effective in circumventing 
P-gp-mediated MDR. One possible reason is that the effective POPs may have 
synergistic effect in crude extract and therefore largely elevated the effect of crude 
extract. This remains unconfirmed and awaits further investigation. 
We also investigated the in vitro cytotoxicity and P-gp-mediated MDR reversal effect 
of crude extract, artificial mixture and the three fractions in MCF-7 cells. The result 
showed that crude extract and fraction 3 were cytotoxic at 50 ‘ug/mL and fraction 2 
was cytotoxic at 25 pg/mL. On the other hand, artificial mixture and fraction 1 did 
not induce cytotoxic effect up to 50 pM and 50 ！jg/mL, respectively. Interestingly, the 
artificial mixture containing only POP68, POP69 and POP70 was devoid of any 
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cytotoxic effect up to 50 pM, while fraction 2, containing POP68, POP69 and 1)01)70 
together with other compounds, was found to be cytotoxic at concentration above 25 
•Ug/mL. Therefore, the cytotoxicity induced by fraction 2 should be due to 
compounds other than the three POPs existing in the fraction but not the three major 
POPs. 
The effect of crude extract, artificial mixture and the three fractions in circumventing 
P-gp-mediated MDR were studied using SRB assay. From the result, the crude 
extract and fraction 3 were considered effective in lowering the IC50 value of 
doxorubicin in resistant SW620/Ad300 cells by more than 50% (Table 4.3). In 
contrast, artificial mixture, fraction 1 and fraction 2, were demonstrated to be 
ineffective. The result suggests that combining the ineffective POP68, POP69 and 
POP70, in the case of artificial mixture and fraction 2, remained to be ineffective in 
circumventing P-gp-mediated MDR in vitro. The ineffective fraction 1 also indicated 
that compounds other than POPs in this control fraction did not contribute to the 
P-gp-mediated MDR reversal effect. Therefore, the P-gp-mediated MDR reversal 
effect of crude extract was actually come from the POPs other than POP68, POP69 
and POP70, most probably due to the combination of all effective POPs in 
modulating P-gp (such as POP52, POP53, POP55, POP56, POP62, POP63, POP65, 
POP66, POP86, POP87 and POP88). However, since the biotransformation of the 
ineffective POP68, POP69 and POP70 to the effective POPs were excluded in the in 
vitro investigation, in vivo anti-tumor study should consider co-administration of 
chemotherapeutics with fraction 2 as well but not only with crude extract or fraction 
3 . 
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Human intestine is an ecologically diverse environment and contains over 400 
distinct species of microbiota.These microbiota produce a wide range of reductive 
and hydrolytic enzymes, in which glucosidase and glucuronidase are the most 
extensively studied hydrolytic enzymes. They are involved in various processes 
occurring in the colon. ^ ^^  The capability of biotransformation of TCMs in the 
gastrointestinal tract arises interests in current researches. Active components could 
be discovered and new mechanisms could be revealed by studying the 
biotransformation of TCMs]60 In our study, the biotransformation of the three major 
POPs (POP68, POP69 and POP70) were investigated by incubating them 
individually or in combination in intestinal microbiota solution. From our result, only 
monosaccharide were cleaved in all three major POPs and became effective POP62, 
POP63 and POP66, while POP53, POP55 or POP56 were not formed when 
incubated with the intestinal microbiota. Fraction 2 containing POP68, POP68 and 
POP70 were found to be converted to POP62, POP63 and POP66 respectively after 
oral administration in mice whereas there were no metabolites detected in the blood 
circulation after i.v. administration in mice (data not shown). This showed evidence 
that only POPs administered orally could be metabolized by intestinal microbiota and 
then absorbed through intestine. Heat-inactivated intestinal microbiota solution can 
be included as the negative control to demonstrate the biotransformation is resulted 
from the enzymatic reactions by microbiota in future study. Importantly, these 
biotransformations of POP68 to POP62, POP69 to POP62 and/or POP70 to POP66 
in the intestine were shown to enable the ineffective POPs POP68, POP69 and 
POP70 to become effective after oral administration. Subsequently, the composition 
of effective POPs in crude extract wil l be largely increased, as shown in the 
chromatograms in Figure 4.1. This is likely to be the explanation why the crude 
100 
Chapter 4. BtTccl of crude extract and three major polyoxypregnane c o i n p o u i i d s 
extract of M. tenacissima is effective in TCM formulation to enhance the cytotoxic 
effect of chemotherapeutic drugs. 
We have provided the evidence that the crude extract of M tenacissima can be used 
to enhance the efficacy of the co-administered chemotherapeutic drugs in resistant 
cancer cells due to its P-gp inhibitory activity. In treating colon cancer, one might 
specifically target colon site and administer chemotherapeutics/^^ The three major 
POPs POP68, POP69 and POP70 in extract of M. tenacissima or fraction 2 can also 
be considered to serve as prodrug as they are the inactive derivative of active POPs 
and help modulate the pharmacokinetics of the effective POPs after 
administration. 156 The co-administration of a mixture of POPs or the extract of M 
tenacissima together with chemotherapeutics such as irinotecan can be investigated 
in enhancing the cytotoxic effect to colon cancer cells. 
Comparing the pure POP treatment group and the artificial mixture treatment group, 
there was a difference between the metabolite formation percentage of the 
metabolites POP62 and POP66, whereas the metabolite formation percentages of 
POP63 were comparable in these two treatment groups. The metabolite formation 
percentages of POP62 and POP66 in artificial mixture group were lower than that in 
pure POP treatment group, around 10% decrease for POP66 and around 5% decrease 
for POP62 (Figure 4.3). Therefore, the metabolite formation percentage of POPs 
might be regulated by the co-existence of other POPs. 
In crude extract treatment group, the metabolic rates of POP68, POP69 and POP70 
were higher than 20%, 40% and 30% respectively as shown in Figure 4.4. POP62, 
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the metabolite derived from POP68, was found to be the most abundant among all 
metabolites detected after the transformation, whereas POP63 and POP66 had similar 
metabolite formation percentages (Figure 4.3). However, the metabolite formation 
percentage of POP62, POP63 and POP66 did not match the metabolic rate of their 
corresponding parental compounds. The metabolite formation percentage of POP62 
at 4 h was around 20%, after subtracting the initial concentration of POP62 found in 
crude extract, which is the concentration detected at 0 h, the net metabolite formation 
percentage was more than 10%. The metabolic rate of POP68 was around 20% at 4 h 
while the metabolite formation percentage of POP62 was 13% at 4 h after subtracting 
the initial concentration of POP62, suggesting the presence of some other forms of 
metabolites not derived from hydrolysis. For POP69, while its metabolic rate was 
found to be the highest (40%), the metabolite formation percentage of POP63 was 
only around around 7% after subtracting the initial concentration and there was 
approximately 33% loss during degradation. The metabolic rate of POP70 was 
around 30% and its metabolite POP66, after subtracting initial concentration had 
around 5% metabolite formation percentage and there was 25% loss by degradation 
pathways other than hydrolysis. However, the metabolites formed from other 
degradation pathways could not detected in the present study. 
As discussed in Chapter 3, the effective POPs on P-gp-overexpressing cells was 
more pronounced comparing with the cells having normal P-gp expression level. In 
this chapter, after confirming the in vivo biotransformation of the three major POPs 
to their respective effective POPs in circumventing P-gp-mediated MDR, the toxicity 
of fraction 2, a fraction extracted from crude extract and contained POP68, POP69 
and POP70, was studied using male BALB/c mice. The three major POPs in fraction 
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2, after oral administration and metabolized by intestinal microbiota, were converted 
to effective POPs. Figure 4.6 and Figure 4.7 showed that both the weight and the 
physical appearance of various organs in the treated mice were not significantly 
changed relative to the control groups. For intravenous administration, the parental 
POPs, POP68, POP69 and POP70, had by-passed the absorption sites at the intestine, 
and were therefore not metabolized by the intestinal microbiota. The three major 
POPs, as shown in Figure 4.6 and Figure 4.7, did not induce toxicity towards various 
organs as well. 
Due to the limited time for the present study, the pharmacokinetics studies of the 
three major POPs and their metabolically formed effective POPs have not been 
completed and are currently under progress. Furthermore, the in vivo anti-tumor 
effect of co-administrating anti-cancer chemotherapeutics and POPs await further 
investigation to support the MDR reversal potential of fraction 2 and crude extract. 
In summary, crude extract of M. tenacissima was effective in circumventing 
P-gp-mediated MDR, and the effect was mainly contributed by fraction 3, which 
contains all the POPs other than the three abundant POP68, POP69 and POP70. 
Fraction 1 and fraction 2 were ineffective in modulating P-gp activity, suggesting 
that compounds other than POPs (fraction 1) and POP68, POP69 and POP70 
(fraction 2) did not contribute to the P-gp-mediated MDR reversal effect of the 
herbal extract. However, POP68, POP69 and POP70 composed a large proportion, 
more than 50%, in the crude extract and the synergistic effect of those effective POPs 
in fraction 3 in relatively very low quantities may not fully explain the MDR reversal 
effect of M tenacissima. TCM often administered in decoction orally and therefore 
103 
Chapter 4. tZtTecl of crude extract and three major polyoxypregnane conipoiinds 
the biotransformation of POP68, POP69 and POP70 were studied. By incubating 
these three POPs with intestinal microbiota solution, their respective metabolites 
POP62, POP63 and POP66 were formed and reached 13%, 7% and 5% respectively 
at 4 h. These three metabolites were also found in systemic circulation after oral 
administration but not i.v. administration of fraction 2. Since these three most 
abundant POPs were found to be converted into effective POPs in the intestine, the 
active components of M. tenacissima should be both the naturally existing effective 
POPs and POPs which are effective after biotransformation in vivo. More importantly, 
these three most abundant POPs have been proved to be safe without inducing any 
toxicity towards various organs in mice after oral and i.v. administration. Based on 
all these results, our findings successfully demonstrated that M tenacissima was 
effective and safe to be used as MDR reversing agent. 
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CHAPTER 5. FINAL DISCUSSION AND CONCLUSIONS 
Multidrug resistance remains a major obstacle in cancer chemotherapy. MDR 
reversing agents have been the research focus for decades to circumvent MDR in 
resistant cancer cells. Although three generations of MDR reversing agents have 
already been developed, all of them failed to circumvent cancer MDR clinically. 
Natural compounds including active components found in TCM is regarded as the 
‘‘fourth generation" of the MDR reversing agents and fuel hope in reducing adverse 
effect as well as circumventing MDR in chemotherapy. ^^  
M. tenacissima has been used as TCM and also traditional folk medicinal herbs in 
Yunnan province in China for thousands of years. In our study, 30 POPs have been 
isolated from M. tenaccisima, 11, 6 and 3 POPs from the 30 POPs were found to be 
effective in circumventing P-gp-, MRP1-, and ABCG2-mediated MDR, respectively. 
Among the effective POPs, POP65, POP86 and POP87 were effective in modulating 
the efflux of all three ABC transporters whereas most known efflux transporter 
inhibitors identified were only effective in inhibiting one ABC transporter. Therefore, 
based on the results obtained from the present study, synergistic effect among POPs, 
especially those potent POPs, is worth to be studied and thus the effect produced by 
their combinational use is also needed to be further investigated. Moreover, the 
structure activity relationship has been observed, especially, an acetyl group at R2 
position of POPs was found as the primary core structure for the effectiveness in 
circumventing P-gp-mediated MDR, and further in-depth studies are warranted to 
confirm such relationship. 
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Six POPs, namely POP53, POP55, POP56, POP62, POP63 and POP66, were found 
to be effective in modulating P-gp. Al l these six POPs significantly enhanced the 
cytotoxicity of P-gp substrate doxorubicin in P-gp overexpressing resistant 
drug-selected SW620/Ad300 and MDRl transfected HEK293 MDRl cells but not 
affected the sensitivity towards doxorubicin in the corresponding control cell lines, 
SW620 and HEK293 pcDNA3. The results obtained from these two pairs of cell 
lines confirm the action of these six POPs in reversing MDR in P-gp overexpressing 
cancer cells but not the cells with normal P-gp expression level. The mechanistic 
studies demonstrated that these six POPs significantly increased the intracellular 
concentration of a P-gp substrate, rhodamine-123, and was further revealed that these 
six POPs stimulated the P-gp ATPase activities, leading to inhibiting the 
P-gp-mediated efflux, while not regulating P-gp protein expression level. 
TCM herbs were well known with the intake of the decoction combined with 
multi-herbs consisting multi-components. In the present study, various mixtures, 
including M. tenacissima crude extract, fraction 1 containing components other than 
POPs, fraction 2 containing the three most abundant POPs and fraction 3 containing 
all the remaining effective and ineffective POPs in a very low quantity, were studied 
in addition to the isolated individual POPs. The crude extract and fraction 3 were 
found to be effective in circumventing P-gp-mediated MDR while fraction 1 and 
fraction 2 were ineffective. Hence, the MDR reversal effect of the crude extract came 
from fraction 3, and most probably due to the synergistic effect among the effective 
POPs although the total content of these effective POPs were very low in the fraction. 
More intriguingly and importantly, it was demonstrated that the three most abundant 
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POPs, POP68, POP69 and POP70, were metabolically converted to three effective 
POPs, POP62, POP63 and POP66 respectively, by human intestinal microbiota. Such 
metabolic biotransformation was further confirmed by the determination of all three 
effective POPs (POP62, POP63 and POP66) in blood circulation with relatively high 
concentrations in mice after oral administration of fraction 2. Our findings revealed 
that active components of TCM herbs can be either compound(s) present in herb 
and/or existing as prodrug(s) which can only be effective after metabolic 
biotransformation in the body. Last but not least, fraction 2 did not induce toxicity 
towards various organs in mice. 
TCM herbs, having characteristics of multi-compounds, multi-targets and 
multi-actions, are often hard to be evaluated. Nonetheless, our study of M. 
tenacissima provided a good example for how to identify the real in vivo effective 
ingredients responsible for the herbal activities. The effective POPs identified from 
M. tenacissima can be considered as potential lead compounds for further 
investigation and development of a new generation of ABC transporter inhibitor to 
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